

# Annual Shareholder Report

December 31, 2022



---

Share Class                      Primary                      Service

---

## Federated Hermes Kaufmann Fund II

---

A Portfolio of Federated Hermes Insurance Series

Dear Valued Shareholder,

We are pleased to present the Annual Shareholder Report for your fund covering the period from January 1, 2022 through December 31, 2022. This report includes Management's Discussion of Fund Performance, a complete listing of your fund's holdings, performance information and financial statements along with other important fund information.

As a global leader in active, responsible investment management, Federated Hermes is guided by our conviction that responsible investing is the best way to create wealth over the long term. The company provides capabilities across a wide range of asset classes to investors around the world.

In addition, [FederatedInvestors.com](https://www.federatedinvestors.com) offers quick and easy access to valuable resources that include timely fund updates, economic and market insights from our investment strategists and financial planning tools. You can also access many of those insights by following us on Twitter (@FederatedHermes) and LinkedIn.

Thank you for investing with us. We hope you find this information useful and look forward to keeping you informed.

Sincerely,

A handwritten signature in black ink, appearing to read "John B. Fisher".

John B. Fisher, President

**CONTENTS**

Management’s Discussion of Fund Performance .....	1
Portfolio of Investments Summary Table .....	3
Portfolio of Investments .....	4
Financial Highlights .....	10
Statement of Assets and Liabilities .....	12
Statement of Operations .....	13
Statement of Changes in Net Assets.....	14
Notes to Financial Statements.....	15
Report of Independent Registered Public Accounting Firm.....	22
Shareholder Expense Example .....	23
Board of Trustees and Trust Officers .....	24
Evaluation and Approval of Advisory Contract.....	28
Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness .....	33
Voting Proxies on Fund Portfolio Securities .....	34
Quarterly Portfolio Schedule .....	34

## Management's Discussion of Fund Performance (unaudited)

The total return of Federated Hermes Kaufmann Fund II (the "Fund"), based on net asset value for the 12-month reporting period ended December 31, 2022, was -30.09% for the Primary Shares and -30.26% for the Service Shares. The Fund's benchmark, the Russell Midcap<sup>®</sup> Growth Index (RMCGI),<sup>1</sup> a broad-based securities market index, had a total return of -26.72% for the period. The total return of the Morningstar Insurance Mid-Cap Growth Funds Average (MIMCGFA),<sup>2</sup> the peer group average for the Fund, was -29.17%. The Fund's and MIMCGFA's total returns for the most recently completed fiscal year reflected actual cash flows, transaction costs and expenses, which were not reflected in the total return of the RMCGI.

During the reporting period, the Fund's investment strategy focused on stock selection, sector exposure and country allocation. These were the most significant factors affecting the Fund's performance relative to the RMCGI.

The following discussion will focus on the Fund's Primary Shares relative to the RMCGI.

### MARKET OVERVIEW

During the reporting period, the U.S. economy and most significant westernized economies saw inflation continue to be the primary headwind to economic growth. Inflationary pressures persisted again due to the impact from record monetary and fiscal stimulus as well as the Eastern European conflict along with regulatory restrictions causing supply disruptions. This inflationary pressure caused most global central banks to pursue aggressive monetary tightening policies in 2022. This pressure seemed to ease a bit at the end of the year as some economic statistics showed potential signs of inflation peaking and heading lower.

The U.S. equity markets were negative for the reporting period, led by mid-cap stocks represented by the Russell Midcap<sup>®</sup> Index<sup>3</sup> (-17.32%), followed by the S&P 500 Index<sup>4</sup> (-18.11%), followed by large-cap stocks represented by the Russell 1000<sup>®</sup> Index<sup>5</sup> (-19.13%), followed by small-cap stocks represented by the Russell 2000<sup>®</sup> Index<sup>6</sup> (-20.44%). Mid-cap growth stocks underperformed mid-cap value stocks during the period.

The best-performing RMCGI sectors during the reporting period were Energy (+59.15%), Utilities (+2.87%) and Consumer Staples (-3.72%). The weakest-performing sectors during the reporting period were Communication Services (-55.59%), Information Technology (-33.11%) and Consumer Discretionary (-29.20%).

### STOCK SELECTION

The five stocks that contributed the most to the Fund's performance versus the RMCGI were: arGEN-X SE, Rhythm Pharmaceuticals Inc., New Fortress Energy Inc., Match Group, Inc. and Datadog Inc.

The five stocks that most negatively affected Fund performance were: Shopify Inc., Tandem Diabetes Care Inc., Enphase Energy Inc., Advanced Micro Devices Inc. and GDS Holdings Ltd.

### SECTOR EXPOSURE

At the end of the reporting period, approximately 57% of the portfolio was invested in four large sectors: Health Care, Information Technology, Consumer Discretionary and Financials. These sectors have historically provided good opportunities for bottom-up growth investors. During the reporting period, stock selection in Health Care and Technology had a negative impact on performance. The cash position of the Fund was approximately 10% on average throughout the reporting period, which aided relative performance during a down market period.

### COUNTRY ALLOCATION

The reporting period ended with approximately 13% of the Fund invested in non-U.S. holdings. During the reporting period, stock selection in foreign companies<sup>7</sup> was a negative contributor to Fund performance. However, the allocation outside the U.S. helped Fund performance relative to the RMCGI.

<sup>1</sup> Please see the footnotes to the line graph below for definitions of, and further information about, the RMCGI.

<sup>2</sup> Please see the footnotes to the line graph below for definitions of, and further information about, the MIMCGFA.

<sup>3</sup> The Russell Midcap<sup>®</sup> Index measures the performance of the mid-cap segment of the U.S. equity universe. The Russell Midcap<sup>®</sup> Index is a subset of the Russell 1000<sup>®</sup> Index. It includes approximately 800 of the smallest securities based on a combination of their market cap and current index membership.\*

<sup>4</sup> The S&P 500 is a capitalization-weighted index of 500 stocks designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries.\*

<sup>5</sup> The Russell 1000<sup>®</sup> Index measures the performance of the large-cap segment of the U.S. equity universe. It includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.\*

<sup>6</sup> The Russell 2000<sup>®</sup> Index measures the performance of the small-cap segment of the U.S. equity universe. It includes approximately 2000 of the smallest securities based on a combination of their market cap and current index membership.\*

<sup>7</sup> International investing involves special risks including currency risk, increased volatility, political risks and differences in auditing and other financial standards.


\* The index is unmanaged, and it is not possible to invest directly in an index.

## FUND PERFORMANCE AND GROWTH OF A \$10,000 INVESTMENT

The graph below illustrates the hypothetical investment of \$10,000<sup>1</sup> in the Federated Hermes Kaufmann Fund II (the “Fund”) from December 31, 2012 to December 31, 2022, compared to the Russell Midcap<sup>®</sup> Growth Index (RMCGI)<sup>2</sup> and the Morningstar Insurance Mid-Cap Growth Funds Average (MIMCGFA).<sup>3</sup> The Average Annual Total Return table below shows returns for each class averaged over the stated periods.

### GROWTH OF A \$10,000 INVESTMENT

#### Growth of \$10,000 as of December 31, 2022



The Fund offers multiple share classes whose performance may be greater than or less than its other share class(es) due to differences in sales charges and expenses.

#### Average Annual Total Returns for the Period Ended 12/31/2022

	1 Year	5 Years	10 Years
Primary Shares	-30.09%	5.10%	10.81%
Service Shares	-30.26%	4.85%	10.53%
RMCGI	-26.72%	7.64%	11.41%
MIMCGFA	-29.17%	7.11%	10.22%

**Performance data quoted represents past performance which is no guarantee of future results. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Performance of a variable investment option changes over time and current performance may be lower or higher than what is stated. For current to the most recent month-end performance, contact your insurance company. The performance information presented does not include the charges and expenses imposed by the insurance company under the variable insurance product contract. The inclusion of such charges would lower performance. Please refer to the variable insurance product prospectus for a complete listing of these expenses. Fund shares are available exclusively as a funding vehicle for life insurance companies writing variable life insurance policies and variable annuity contracts. Variable investment options are not obligations of or guaranteed by any bank and are not federally insured.**

- <sup>1</sup> The Fund’s performance assumes the reinvestment of all dividends and distributions. The RMCGI and MIMCGFA have been adjusted to reflect reinvestment of dividends on securities in the index and average.
- <sup>2</sup> The RMCGI measures the performance of the mid-cap growth segment of the U.S. equity universe. It includes those Russell Midcap<sup>®</sup> Index companies with higher price-to-book ratios and higher forecasted growth values. The RMCGI is constructed to provide a comprehensive and unbiased barometer of the mid-cap growth market. The RMCGI is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true mid-cap growth market. The RMCGI is not adjusted to reflect sales charges, expenses or other fees that the Securities and Exchange Commission requires to be reflected in the Fund’s performance. The index is unmanaged and unlike the Fund, is not affected by cash flows. It is not possible to invest directly in an index.
- <sup>3</sup> Morningstar figures represent the average of the total returns reported by all the funds designated by Morningstar as falling into the respective category indicated. They do not reflect sales charges. The Morningstar figures in the Growth of a \$10,000 Investment line graph are based on historical return information published by Morningstar and reflect the return of the funds comprising the category in the year of publication. Because the funds designated by Morningstar as falling into the category can change over time, the Morningstar figures in the line graph may not match the Morningstar figures in the Average Annual Total Returns table, which reflect the return of the funds that currently comprise the category.

## Portfolio of Investments Summary Table (unaudited)

At December 31, 2022, the Fund's sector composition<sup>1</sup> was as follows:

Sector Composition	Percentage of Total Net Assets
Health Care	39.2%
Financials	7.9%
Consumer Discretionary	6.3%
Industrials	5.5%
Real Estate	5.4%
Information Technology	4.3%
Energy	4.2%
Materials	4.1%
Utilities	2.8%
Consumer Staples	1.8%
Communication Services	0.3%
U.S. Treasury Notes	2.7%
Securities Lending Collateral <sup>2</sup>	0.3%
Cash Equivalents <sup>3</sup>	16.1%
Other Assets and Liabilities—Net <sup>4</sup>	(0.9)%
<b>TOTAL</b>	<b>100%</b>

- 1 Except for Securities Lending Collateral, Cash Equivalents and Other Assets and Liabilities, sector classifications are based upon, and individual portfolio securities are assigned to, the classifications of the Global Industry Classification Standard (GICS), except that the Adviser assigns a classification to securities not classified by the GICS and to securities for which the Adviser does not have access to the classification made by the GICS.
- 2 Represents cash collateral received for portfolio securities on loan that may be invested in affiliated money market funds, other money market instruments and/or repurchase agreements.
- 3 Cash Equivalents include any investments in money market mutual funds and/or overnight repurchase agreements other than those representing securities lending collateral.
- 4 Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

# Portfolio of Investments

December 31, 2022

Shares or Principal Amount		Value
	<b>COMMON STOCKS—81.4%</b>	
	<b>Communication Services—0.3%</b>	
2,000	<sup>1</sup> Take-Two Interactive Software, Inc.	\$ 208,260
5,300	<sup>1</sup> ZoomInfo Technologies, Inc.	159,583
	TOTAL	367,843
	<b>Consumer Discretionary—6.3%</b>	
7,500	<sup>1</sup> Airbnb, Inc.	641,250
3,000	<sup>1</sup> Alibaba Group Holding Ltd., ADR	264,270
11,900	<sup>1</sup> Amazon.com, Inc.	999,600
466	<sup>1</sup> Chipotle Mexican Grill, Inc.	646,570
4,156	Choice Hotels International, Inc.	468,132
1,500	<sup>1</sup> Etsy, Inc.	179,670
5,900	<sup>1</sup> Floor & Decor Holdings, Inc.	410,817
7,400	<sup>1</sup> Las Vegas Sands Corp.	355,718
1,700	<sup>1</sup> Lululemon Athletica, Inc.	544,646
300	<sup>1</sup> Mercadolibre, Inc.	253,872
7,230	Moncler SPA	384,858
617,686	NagaCorp Ltd.	544,539
11,100	<sup>1</sup> Planet Fitness, Inc.	874,680
32,100	<sup>1,2</sup> Sportradar Group AG	319,716
261	Vail Resorts, Inc.	62,209
13,300	Wingstop, Inc.	1,830,346
5,100	<sup>1</sup> YETI Holdings, Inc.	210,681
	TOTAL	8,991,574
	<b>Consumer Staples—1.8%</b>	
910	Costco Wholesale Corp.	415,415
17,800	Philip Morris International, Inc.	1,801,538
26,700	<sup>1</sup> The Duckhorn Portfolio, Inc.	442,419
	TOTAL	2,659,372
	<b>Energy—4.2%</b>	
12,000	Cheniere Energy, Inc.	1,799,520
69,300	<sup>2</sup> New Fortress Energy, Inc.	2,939,706
5,270	Pioneer Natural Resources, Inc.	1,203,615
3,012	Williams Cos., Inc.	99,095
	TOTAL	6,041,936
	<b>Financials—7.9%</b>	
27,900	Apollo Global Management, Inc.	1,779,741
1,740	BlackRock, Inc.	1,233,016
234,158	<sup>1</sup> Blue Owl Capital, Inc.	2,482,075
62,400	FinecoBank Banca Fineco SPA	1,039,930
20,700	Hamilton Lane Alliance Holdings I, Inc.	1,322,316
20,600	KKR & Co., Inc., Class Common	956,252
2,222	MSCI, Inc., Class A	1,033,608
4,451	S&P Global, Inc.	1,490,818
	TOTAL	11,337,756
	<b>Health Care—38.8%</b>	
4,600	Abbott Laboratories	505,034
23,300	<sup>1</sup> Acrivon Therapeutics, Inc.	268,416
32,712	<sup>1</sup> Albireo Pharma, Inc.	706,906
66,400	<sup>1</sup> Alector, Inc.	612,872
33,480	<sup>1</sup> Amphastar Pharmaceuticals, Inc.	938,110
22,901	<sup>1</sup> Amylyx Pharmaceuticals, Inc.	846,192
33,186	<sup>1,2</sup> AnaptysBio, Inc.	1,028,434
57,800	<sup>1</sup> Annexon, Inc.	298,826
4,600	<sup>1</sup> Apellis Pharmaceuticals, Inc.	237,866

Shares or Principal Amount		Value
	COMMON STOCKS—continued	
	<b>Health Care—continued</b>	
8,000	<sup>1</sup> Apollo Endosurgery, Inc.	\$ 79,760
65,229	<sup>1,2</sup> Arcturus Therapeutics Holdings, Inc.	1,106,284
21,149	<sup>1</sup> Argenx SE	7,969,434
66,600	<sup>1</sup> aTyr Pharma, Inc.	145,854
36,300	<sup>1,2</sup> Avidity Biosciences LLC	805,497
7,000	<sup>1</sup> Century Therapeutics, Inc.	35,910
7,369	<sup>1</sup> Century Therapeutics, Inc.	37,803
13,352	<sup>1</sup> Cerevel Therapeutics Holdings	421,122
12,900	<sup>1</sup> Chinook Therapeutics, Inc.	337,980
56,475	<sup>1,3</sup> Contra Akouos, Inc., Rights	44,615
93,806	<sup>1</sup> Corcept Therapeutics, Inc.	1,905,200
5,758	<sup>1,2</sup> CRISPR Therapeutics AG	234,063
14,500	Danaher Corp.	3,848,590
3,500	<sup>1</sup> Denali Therapeutics, Inc.	97,335
32,100	<sup>1</sup> Dexcom, Inc.	3,635,004
194,638	<sup>1</sup> Dynavax Technologies Corp.	2,070,948
2,900	<sup>1</sup> EDAP TMS SA, ADR	30,914
6,800	Eli Lilly & Co.	2,487,712
3,200	<sup>1</sup> Fate Therapeutics, Inc.	32,288
14,100	<sup>1</sup> Fusion Pharmaceuticals, Inc.	44,415
47,600	<sup>1,2</sup> Gamida Cell Ltd.	61,404
3,750	<sup>1</sup> Genmab A/S	1,588,416
14,700	<sup>1</sup> Genmab A/S, ADR	622,986
18,728	<sup>1</sup> Gracell Biotechnologies, Inc., ADR	43,074
8,060	<sup>1,2</sup> Graphite Bio, Inc.	26,759
7,582	<sup>1</sup> Guardant Health, Inc.	206,230
36,200	<sup>1</sup> IDEAYA Biosciences, Inc.	657,754
1,175	<sup>1</sup> IDEXX Laboratories, Inc.	479,353
2,800	<sup>1</sup> Illumina, Inc.	566,160
10,000	<sup>1,4</sup> Immatics N.V.	87,100
4,901	<sup>1</sup> Insulet Corp.	1,442,805
28,579	<sup>1</sup> Intellia Therapeutics, Inc.	997,121
1,800	<sup>1</sup> Intuitive Surgical, Inc.	477,630
4,307	<sup>1,3</sup> Laronde, Inc.	93,397
33,800	<sup>1</sup> Legend Biotech Corp., ADR	1,687,296
13,200	<sup>1,2</sup> Lyell Immunopharma, Inc.	45,804
49,295	<sup>1,2</sup> Merus N.V.	762,594
17,225	<sup>1</sup> Minerva Neurosciences, Inc.	27,388
5,700	<sup>1</sup> Morphic Holding, Inc.	152,475
3,700	<sup>1</sup> Natera, Inc.	148,629
3,200	Novo Nordisk A/S	433,280
14,887	<sup>1</sup> Orchard Therapeutics PLC	5,523
195,900	<sup>1</sup> Orchard Therapeutics PLC, ADR	72,679
6,500	<sup>1</sup> Privia Health Group, Inc.	147,615
2,975	<sup>1</sup> Prometheus Biosciences, Inc.	327,250
35,326	<sup>1</sup> Regulus Therapeutics, Inc.	48,397
5,350	<sup>1</sup> Repligen Corp.	905,809
84,174	<sup>1</sup> Rezolute, Inc.	174,240
113,900	<sup>1,2</sup> Rhythm Pharmaceuticals, Inc.	3,316,768
2,514	<sup>1</sup> Sana Biotechnology, Inc.	9,930
10,600	<sup>1</sup> Sarepta Therapeutics, Inc.	1,373,548
40,914	<sup>1</sup> Scynexis, Inc.	63,826
353,300	<sup>1</sup> Seres Therapeutics, Inc.	1,978,480
1,750	Stryker Corp.	427,858
44,500	<sup>1</sup> Ultragenyx Pharmaceutical, Inc.	2,061,685
14,900	<sup>1</sup> Veeva Systems, Inc.	2,404,562

Shares or Principal Amount		Value
	COMMON STOCKS—continued	
	<b>Health Care—continued</b>	
32,900	<sup>1,2</sup> Verve Therapeutics, Inc.	\$ 636,615
14,800	<sup>1,2</sup> Zentalis Pharmaceuticals, LLC	298,072
	TOTAL	55,673,896
	<b>Industrials—5.5%</b>	
40,000	<sup>1</sup> CoStar Group, Inc.	3,091,200
1,600	Deere & Co.	686,016
9,975	HEICO Corp.	1,532,559
15,130	<sup>1</sup> Mercury Systems, Inc.	676,916
4,154	Quanta Services, Inc.	591,945
3,700	Trane Technologies PLC	621,933
11,639	<sup>1</sup> Upwork, Inc.	121,511
5,415	Wabtec Corp.	540,471
	TOTAL	7,862,551
	<b>Information Technology—4.3%</b>	
1,000	<sup>1</sup> Adobe, Inc.	336,530
400	<sup>1</sup> Advanced Micro Devices, Inc.	25,908
8,916	<sup>1</sup> Coupa Software, Inc.	705,879
260	<sup>1</sup> CrowdStrike Holdings, Inc.	27,376
50,300	<sup>1,2</sup> GDS Holdings Ltd., ADR	1,037,186
200	<sup>1</sup> Keysight Technologies, Inc.	34,214
700	Marvell Technology, Inc.	25,928
300	<sup>1</sup> Okta, Inc.	20,499
308	<sup>1</sup> Palo Alto Networks, Inc.	42,978
7,600	<sup>1</sup> Q2 Holdings, Inc.	204,212
2,237	<sup>1</sup> ServiceNow, Inc.	868,560
18,000	<sup>1</sup> Shopify, Inc.	624,780
122	<sup>1</sup> ShotSpotter, Inc.	4,127
2,089	<sup>1</sup> Splunk, Inc.	179,842
5,630	<sup>1</sup> Tyler Technologies, Inc.	1,815,169
1,500	<sup>1</sup> Workday, Inc.	250,995
	TOTAL	6,204,183
	<b>Materials—4.1%</b>	
32,100	Agnico Eagle Mines Ltd.	1,668,879
1,750	Albemarle Corp.	379,505
48,100	Barrick Gold Corp.	826,358
30,097	Newmont Corp.	1,420,578
7,000	Sherwin-Williams Co.	1,661,310
	TOTAL	5,956,630
	<b>Real Estate—5.4%</b>	
26,600	Americold Realty Trust, Inc.	753,046
9,650	Crown Castle International Corp.	1,308,926
24,650	Easterly Government Properties, Inc.	351,756
8,900	National Storage Affiliates Trust	321,468
54,177	Physicians Realty Trust	783,941
11,900	ProLogis, Inc.	1,341,487
7,300	Ryman Hospitality Properties, Inc.	596,994
17,842	STAG Industrial, Inc.	576,475
1,526	Sun Communities, Inc.	218,218
44,400	VICI Properties, Inc.	1,438,560
	TOTAL	7,690,871
	<b>Utilities—2.8%</b>	
7,300	American Electric Power Co., Inc.	693,135
11,400	Duke Energy Corp.	1,174,086
25,200	NextEra Energy, Inc.	2,106,720
	TOTAL	3,973,941
	TOTAL COMMON STOCKS (IDENTIFIED COST \$80,559,026)	116,760,553



Shares or Principal Amount		Value
	U.S. TREASURIES—2.7%	
	<b>U.S. Treasury Notes—2.7%</b>	
\$ 3,500,000	United States Treasury Note, 4.125%, 11/15/2032	\$ 3,569,453
300,000	United States Treasury Note, 4.375%, 10/31/2024	299,112
	TOTAL U.S. TREASURIES (IDENTIFIED COST \$3,892,625)	3,868,565
	PREFERRED STOCKS—0.3%	
	<b>Health Care—0.3%</b>	
53,840	<sup>3</sup> CeQur SA	297,410
32,229	Regulus Therapeutics, Inc.	44,154
	TOTAL PREFERRED STOCKS (IDENTIFIED COST \$409,029)	341,564
	<sup>1</sup> WARRANTS—0.1%	
	<b>Health Care—0.1%</b>	
21,500	Catabasis Pharmaceuticals, Inc., Warrants, Expiration Date 6/22/2023	150
11,450	Catabasis Pharmaceuticals, Inc., Warrants, Expiration Date 2/8/2024	3,237
5,696	Rezolute, Inc., Warrants, Expiration Date 10/8/2027	3,452
1,400	Rezolute, Inc., Warrants, Expiration Date 1/1/2099	2,898
44,952	Rezolute, Inc., Warrants, Expiration Date 12/31/2099	93,051
2,520	Scynexis, Inc., Warrants, Expiration Date 3/8/2023	0
26,500	Scynexis, Inc., Warrants, Expiration Date 5/21/2024	1,200
53,000	Scynexis, Inc., Warrants, Expiration Date 1/1/2099	82,680
644	Scynexis, Inc., Warrants, Expiration Date 4/26/2029	570
	TOTAL WARRANTS (IDENTIFIED COST \$511,056)	187,238
	REPURCHASE AGREEMENTS—16.4%	
\$ 388,239	Interest in \$1,350,000,000 joint repurchase agreement 4.30%, dated 12/30/2022 under which Bank of Montreal will repurchase securities provided as collateral for \$1,350,645,000 on 1/3/2023. The securities provided as collateral at the end of the period held with BNY Mellon as tri-party agent, were U.S. Government Agency securities with various maturities to 5/20/2072 and the market value of those underlying securities was \$1,379,047,631 (purchased with proceeds from securities lending collateral).	388,239
23,168,000	Interest in \$1,350,000,000 joint repurchase agreement 4.30%, dated 12/30/2022 under which Bank of Montreal will repurchase securities provided as collateral for \$1,350,645,000 on 1/3/2023. The securities provided as collateral at the end of the period held with BNY Mellon as tri-party agent, were U.S. Government Agency securities with various maturities to 5/20/2072 and the market value of those underlying securities was \$1,379,047,631.	23,168,000
	TOTAL REPURCHASE AGREEMENTS (IDENTIFIED COST \$23,556,239)	23,556,239
	TOTAL INVESTMENT IN SECURITIES—100.9% (IDENTIFIED COST \$108,927,975) <sup>5</sup>	144,714,159
	OTHER ASSETS AND LIABILITIES - NET—(0.9)% <sup>6</sup>	(1,303,660)
	TOTAL NET ASSETS—100%	\$143,410,499

An affiliated company is a company in which the Fund, alone or in combination with other funds, has ownership of at least 5% of the voting shares. Transactions with the affiliated companies during the period ended December 31, 2022, were as follows:

Affiliated	Value as of 12/31/2021	Purchases at Cost*	Proceeds from Sales*	Change in Unrealized Appreciation/ Depreciation*	Net Realized Gain/ (Loss)*	Value as of 12/31/2022	Shares Held as of 12/31/2022	Dividend Income*
<b>Health Care:</b>								
Albireo Pharma, Inc.	\$ 805,834	\$ 102,642	\$ (140,530)	\$ 23,130	\$ (84,170)	\$ 706,906	32,712	\$ —
Alector, Inc.	\$ 1,355,239	\$ 95,497	\$ (66,387)	\$ (694,171)	\$ (77,306)	\$ 612,872	66,400	\$ —
Amphastar Pharmaceuticals, Inc.	\$ 768,570	\$ 123,361	\$ (98,840)	\$ 102,159	\$ 42,860	\$ 938,110	33,480	\$ —
AnaptysBio, Inc.	\$ 522,779	\$ 416,261	\$ —	\$ 89,394	\$ —	\$ 1,028,434	33,186	\$ —
Annexon, Inc.	\$ 294,144	\$ 246,403	\$ —	\$ (241,721)	\$ —	\$ 298,826	57,800	\$ —
Arcturus Therapeutics Holdings, Inc.	\$ 1,772,261	\$ 324,022	\$ —	\$ (989,999)	\$ —	\$ 1,106,284	65,229	\$ —
aTyr Pharma, Inc.	\$ 427,658	\$ 20,391	\$ —	\$ (302,195)	\$ —	\$ 145,854	66,600	\$ —
Avidity Biosciences LLC**	\$ 701,215	\$ 135,694	\$ —	\$ (31,412)	\$ —	\$ 805,497	36,300	\$ —
Dynavax Technologies Corp.	\$ 2,924,281	\$ 392,667	\$ (586,426)	\$ (556,095)	\$ (103,479)	\$ 2,070,948	194,638	\$ —
Fusion Pharmaceuticals, Inc.	\$ —	\$ 108,687	\$ —	\$ (64,272)	\$ —	\$ 44,415	14,100	\$ —
Gamida Cell Ltd.**	\$ 297,901	\$ 41,338	\$ (229,648)	\$ 251,459	\$ (299,646)	\$ 61,404	47,600	\$ —
IDEAYA Biosciences, Inc.	\$ 562,419	\$ 145,654	\$ —	\$ (50,319)	\$ —	\$ 657,754	36,200	\$ —
Merus N.V.	\$ 1,326,060	\$ 188,139	\$ (32,048)	\$ (706,214)	\$ (13,343)	\$ 762,594	49,295	\$ —
Minerva Neurosciences, Inc.	\$ 110,378	\$ —	\$ —	\$ (82,990)	\$ —	\$ 27,388	17,225	\$ —
Orchard Therapeutics PLC**	\$ 19,651	\$ —	\$ —	\$ (14,128)	\$ —	\$ 5,523	14,887	\$ —
Orchard Therapeutics PLC, ADR	\$ 229,775	\$ 10,305	\$ —	\$ (167,401)	\$ —	\$ 72,679	195,900	\$ —
Regulus Therapeutics, Inc.**	\$ 101,521	\$ —	\$ —	\$ (57,367)	\$ —	\$ 44,154	32,229	\$ —
Regulus Therapeutics, Inc.	\$ 111,279	\$ —	\$ —	\$ (62,882)	\$ —	\$ 48,397	35,326	\$ —
Rezolute, Inc.	\$ 187,481	\$ 170,818	\$ —	\$ (184,059)	\$ —	\$ 174,240	84,174	\$ —
Rezolute, Inc., Warrants, Expiration Date 10/8/2027	\$ 18,278	\$ —	\$ —	\$ (14,826)	\$ —	\$ 3,452	5,696	\$ —
Rezolute, Inc., Warrants, Expiration Date 1/1/2099	\$ 6,692	\$ —	\$ —	\$ (3,794)	\$ —	\$ 2,898	1,400	\$ —
Rezolute, Inc., Warrants, Expiration Date 12/31/2099	\$ —	\$ 170,773	\$ —	\$ (77,722)	\$ —	\$ 93,051	44,952	\$ —
Rhythm Pharmaceuticals, Inc.	\$ 351,765	\$ 1,254,485	\$ (345,057)	\$ 2,182,950	\$ (127,375)	\$ 3,316,768	113,900	\$ —
Scynexis, Inc.	\$ 245,647	\$ 1,932	\$ —	\$ (183,753)	\$ —	\$ 63,826	40,914	\$ —
Scynexis, Inc., Warrants, Expiration Date 3/8/2023	\$ 648	\$ —	\$ —	\$ (648)	\$ —	\$ —	2,520	\$ —
Scynexis, Inc., Warrants, Expiration Date 5/21/2024	\$ 57,375	\$ —	\$ —	\$ (56,175)	\$ —	\$ 1,200	26,500	\$ —
Scynexis, Inc., Warrants, Expiration Date 1/1/2099	\$ 323,300	\$ —	\$ —	\$ (240,620)	\$ —	\$ 82,680	53,000	\$ —
Scynexis, Inc., Warrants, Expiration Date 4/26/2029	\$ —	\$ —	\$ —	\$ 570	\$ —	\$ 570	644	\$ —
Seres Therapeutics, Inc.	\$ 1,303,645	\$ 696,237	\$ (22,682)	\$ 25,828	\$ (24,548)	\$ 1,978,480	353,300	\$ —
Ultragenyx Pharmaceutical, Inc.**	\$ 3,666,324	\$ 251,891	\$ (267,486)	\$ (1,662,706)	\$ 73,662	\$ 2,061,685	44,500	\$ —
<b>Information Technology:</b>								
ShotSpotter, Inc.	\$ —	\$ 3,942	\$ —	\$ 185	\$ —	\$ 4,127	122	\$ —
Affiliated Issuers no longer in the portfolio at period end	\$ 3,520,606	\$ 907,214	\$ (2,791,441)	\$ 528,112	\$ (2,164,491)	\$ —	—	\$ 13,160
<b>TOTAL OF AFFILIATED COMPANIES TRANSACTIONS</b>	<b>\$22,012,726</b>	<b>\$5,808,353</b>	<b>\$(4,580,545)</b>	<b>\$(3,241,682)</b>	<b>\$(2,777,836)</b>	<b>\$17,221,016</b>	<b>1,800,729</b>	<b>\$13,160</b>

\* A portion of the amount shown was recorded when the Fund no longer had ownership of at least 5% of the voting shares.

\*\* At December 31, 2022, the Fund no longer has ownership of at least 5% voting shares.

1 Non-income-producing security.

2 All or a portion of these securities are temporarily on loan to unaffiliated broker/dealers.

3 Market quotations and price valuations are not available. Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Fund's Adviser acting through its Valuation Committee.

4 Denotes a restricted security that either: (a) cannot be offered for public sale without first being registered, or availing of an exemption from registration, under the Securities Act of 1933; or (b) is subject to a contractual restriction on public sales. At December 31, 2022, these restricted securities amounted to \$87,100, which represented 0.1% of total net assets.

5 The cost of investments for federal tax purposes amounts to \$109,373,174.

6 Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

Note: The categories of investments are shown as a percentage of total net assets at December 31, 2022.

Various inputs are used in determining the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1—quoted prices in active markets for identical securities.

Level 2—other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Also includes securities valued at amortized cost.

Level 3—significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used, as of December 31, 2022, in valuing the Fund's assets carried at fair value:

**Valuation Inputs**

	Level 1— Quoted Prices	Level 2— Other Significant Observable Inputs	Level 3— Significant Unobservable Inputs	Total
<b>Equity Securities:</b>				
Common Stocks				
Domestic	\$ 95,739,537	\$ —	\$138,012	\$ 95,877,549
International	8,922,547	11,960,457	—	20,883,004
Preferred Stocks				
International	—	—	297,410	297,410
Domestic	44,154	—	—	44,154
<b>Debt Securities:</b>				
U.S. Treasuries	—	3,868,565	—	3,868,565
Warrants	95,949	91,289	—	187,238
<b>Repurchase Agreements</b>	—	23,556,239	—	23,556,239
<b>TOTAL SECURITIES</b>	<b>\$104,802,187</b>	<b>\$39,476,550</b>	<b>\$435,422</b>	<b>\$144,714,159</b>

The following acronym(s) are used throughout this portfolio:

ADR—American Depositary Receipt

See Notes which are an integral part of the Financial Statements

## Financial Highlights – Primary Shares

(For a Share Outstanding Throughout Each Period)

	Year Ended December 31,				
	2022	2021	2020	2019	2018
<b>Net Asset Value, Beginning of Period</b>	<b>\$24.31</b>	<b>\$25.46</b>	<b>\$22.63</b>	<b>\$18.55</b>	<b>\$19.16</b>
<b>Income From Investment Operations:</b>					
Net investment income (loss) <sup>1</sup>	(0.08)	(0.24)	(0.22)	(0.10)	(0.11)
Net realized and unrealized gain (loss)	(6.87)	0.83	5.27	6.15	0.95
TOTAL FROM INVESTMENT OPERATIONS	(6.95)	0.59	5.05	6.05	0.84
<b>Less Distributions:</b>					
Distributions from net realized gain	(2.26)	(1.74)	(2.22)	(1.97)	(1.45)
<b>Net Asset Value, End of Period</b>	<b>\$15.10</b>	<b>\$24.31</b>	<b>\$25.46</b>	<b>\$22.63</b>	<b>\$18.55</b>
<b>Total Return<sup>2</sup></b>	<b>(30.09)%</b>	<b>2.51%</b>	<b>28.79%</b>	<b>33.82%</b>	<b>3.84%</b>
<b>Ratios to Average Net Assets:</b>					
Net expenses <sup>3</sup>	1.54%	1.50%	1.50%	1.51%	1.52%
Net investment loss	(0.51)%	(0.99)%	(1.01)%	(0.49)%	(0.53)%
Expense waiver/reimbursement <sup>4</sup>	0.00% <sup>5</sup>	—%	—%	—%	—%
<b>Supplemental Data:</b>					
Net assets, end of period (000 omitted)	\$34,430	\$55,366	\$63,502	\$57,988	\$46,160
Portfolio turnover <sup>6</sup>	41%	34%	45%	43%	41%

1 Per share numbers have been calculated using the average shares method.

2 Based on net asset value. Total returns do not reflect any additional fees or expenses that may be imposed by separate accounts of insurance companies or in connection with any variable annuity or variable life insurance contract.

3 Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.

4 This expense decrease is reflected in both the net expense and the net investment income ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.

5 Represents less than 0.01%.

6 Securities that mature are considered sales for purposes of this calculation.

See Notes which are an integral part of the Financial Statements

## Financial Highlights – Service Shares

(For a Share Outstanding Throughout Each Period)

	Year Ended December 31,				
	2022	2021	2020	2019	2018
<b>Net Asset Value, Beginning of Period</b>	<b>\$22.40</b>	<b>\$23.65</b>	<b>\$21.27</b>	<b>\$17.57</b>	<b>\$18.26</b>
<b>Income From Investment Operations:</b>					
Net investment income (loss) <sup>1</sup>	(0.11)	(0.28)	(0.26)	(0.15)	(0.15)
Net realized and unrealized gain (loss)	(6.30)	0.77	4.86	5.82	0.91
TOTAL FROM INVESTMENT OPERATIONS	(6.41)	0.49	4.60	5.67	0.76
<b>Less Distributions:</b>					
Distributions from net realized gain	(2.26)	(1.74)	(2.22)	(1.97)	(1.45)
<b>Net Asset Value, End of Period</b>	<b>\$13.73</b>	<b>\$22.40</b>	<b>\$23.65</b>	<b>\$21.27</b>	<b>\$17.57</b>
<b>Total Return<sup>2</sup></b>	<b>(30.26)%</b>	<b>2.26%</b>	<b>28.48%</b>	<b>33.52%</b>	<b>3.58%</b>
<b>Ratios to Average Net Assets:</b>					
Net expenses <sup>3</sup>	1.79%	1.75%	1.75%	1.76%	1.77%
Net investment loss	(0.73)%	(1.24)%	(1.26)%	(0.74)%	(0.77)%
Expense waiver/reimbursement <sup>4</sup>	0.00% <sup>5</sup>	—%	—%	—%	—%
<b>Supplemental Data:</b>					
Net assets, end of period (000 omitted)	\$108,981	\$150,983	\$169,061	\$129,327	\$105,132
Portfolio turnover <sup>6</sup>	41%	34%	45%	43%	41%

1 Per share numbers have been calculated using the average shares method.

2 Based on net asset value. Total returns do not reflect any additional fees or expenses that may be imposed by separate accounts of insurance companies or in connection with any variable annuity or variable life insurance contract.

3 Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.

4 This expense decrease is reflected in both the net expense and the net investment income ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.

5 Represents less than 0.01%.

6 Securities that mature are considered sales for purposes of this calculation.

See Notes which are an integral part of the Financial Statements

# Statement of Assets and Liabilities

December 31, 2022

## Assets:

Investment in repurchase agreements	\$ 23,556,239
Investment in securities	121,157,920
Investment in securities, at value including \$368,981 of securities loaned and \$17,221,016 of investments in affiliated companies* (identified cost \$108,927,975)	144,714,159
Income receivable	96,280
Receivable for investments sold	45,947
Receivable for shares sold	17,711
<b>TOTAL ASSETS</b>	<b>144,874,097</b>

## Liabilities:

Payable for investments purchased	866,084
Payable for shares redeemed	68,896
Payable to bank	19,128
Payable for collateral due to broker for securities lending (Note 2)	388,239
Payable for investment adviser fee (Note 5)	26,852
Payable for administrative fee (Note 5)	617
Payable for auditing fees	29,038
Payable for distribution services fee (Note 5)	23,596
Accrued expenses (Note 5)	41,148
<b>TOTAL LIABILITIES</b>	<b>1,463,598</b>

Net assets for 10,218,596 shares outstanding \$143,410,499

## Net Assets Consist of:

Paid-in capital	\$108,790,767
Total distributable earnings (loss)	34,619,732
<b>TOTAL NET ASSETS</b>	<b>\$143,410,499</b>

## Net Asset Value, Offering Price and Redemption Proceeds Per Share:

### Primary Shares:

\$34,429,703 ÷ 2,279,713 shares outstanding, no par value, unlimited shares authorized \$15.10

### Service Shares:

\$108,980,796 ÷ 7,938,883 shares outstanding, no par value, unlimited shares authorized \$13.73

\* See information listed after the Fund's Portfolio of Investments.

See Notes which are an integral part of the Financial Statements

# Statement of Operations

Year Ended December 31, 2022

## Investment Income:

Dividends (including \$13,160 received from affiliated companies* and net of foreign taxes withheld of \$23,587)	\$ 1,195,759
Interest	418,796
Net income on securities loaned (Note 2)	26,288
<b>TOTAL INCOME</b>	<b>1,640,843</b>

## Expenses:

Investment adviser fee (Note 5)	2,023,216
Administrative fee (Note 5)	123,658
Custodian fees	42,008
Transfer agent fees	14,475
Directors'/Trustees' fees (Note 5)	2,211
Auditing fees	36,298
Legal fees	11,568
Portfolio accounting fees	67,087
Distribution services fee (Note 5)	289,503
Printing and postage	45,941
Miscellaneous (Note 5)	39,477
<b>TOTAL EXPENSES</b>	<b>2,695,442</b>
Waiver of investment adviser fee (Note 5)	(1,648)
Net expenses	2,693,794
Net investment income (loss)	(1,052,951)

## Realized and Unrealized Gain (Loss) on Investments and Foreign Currency Transactions:

Net realized loss on investments (including net realized loss of \$(2,777,836) on sales of investments in affiliated companies*)	(655,016)
Net realized loss on foreign currency transactions	(7,458)
Net change in unrealized appreciation of investments (including net change in unrealized appreciation of \$(3,241,682) on investments in affiliated companies*)	(60,249,715)
Net change in unrealized appreciation/depreciation of translation of assets and liabilities in foreign currency	(91)
Net realized and unrealized gain (loss) on investments and foreign currency transactions	(60,912,280)
Change in net assets resulting from operations	\$(61,965,231)

\* See information listed after the Fund's Portfolio of Investments.

See Notes which are an integral part of the Financial Statements

## Statement of Changes in Net Assets

Year Ended December 31	2022	2021
<b>Increase (Decrease) in Net Assets</b>		
<b>Operations:</b>		
Net investment loss	\$ (1,052,951)	\$ (2,635,104)
Net realized gain (loss)	(662,474)	21,835,489
Net change in unrealized appreciation/depreciation	(60,249,806)	(13,043,996)
CHANGE IN NET ASSETS RESULTING FROM OPERATIONS	(61,965,231)	6,156,389
<b>Distributions to Shareholders:</b>		
Primary Shares	(5,000,707)	(4,188,149)
Service Shares	(15,209,394)	(12,290,249)
CHANGE IN NET ASSETS RESULTING FROM DISTRIBUTIONS TO SHAREHOLDERS	(20,210,101)	(16,478,398)
<b>Share Transactions:</b>		
Proceeds from sale of shares	30,701,378	31,737,876
Net asset value of shares issued to shareholders in payment of distributions declared	20,210,085	16,478,386
Cost of shares redeemed	(31,674,352)	(64,108,774)
CHANGE IN NET ASSETS RESULTING FROM SHARE TRANSACTIONS	19,237,111	(15,892,512)
Change in net assets	(62,938,221)	(26,214,521)
<b>Net Assets:</b>		
Beginning of period	206,348,720	232,563,241
End of period	\$143,410,499	\$206,348,720

See Notes which are an integral part of the Financial Statements



# Notes to Financial Statements

December 31, 2022

## 1. ORGANIZATION

Federated Hermes Insurance Series (the "Trust") is registered under the Investment Company Act of 1940, as amended (the "Act"), as an open-end management investment company. The Trust consists of six portfolios. The financial statements included herein are only those of Federated Hermes Kaufmann Fund II (the "Fund"), a diversified portfolio. The financial statements of the other portfolios are presented separately. The assets of each portfolio are segregated and a shareholder's interest is limited to the portfolio in which shares are held. Each portfolio pays its own expenses. The Fund offers two classes of shares: Primary Shares and Service Shares. All shares of the Fund have equal rights with respect to voting, except on class-specific matters. Fund shares are available exclusively as a funding vehicle for life insurance companies writing variable life insurance policies and variable annuity contracts. The investment objective of the Fund is capital appreciation.

## 2. SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies consistently followed by the Fund in the preparation of its financial statements. These policies are in conformity with U.S. generally accepted accounting principles (GAAP).

### Investment Valuation

In calculating its net asset value (NAV), the Fund generally values investments as follows:

- Equity securities listed on an exchange or traded through a regulated market system are valued at their last reported sale price or official closing price in their principal exchange or market.
- Fixed-income securities are fair valued using price evaluations provided by a pricing service approved by Federated Equity Management Company of Pennsylvania (the "Adviser").
- Shares of other mutual funds or non-exchange traded investment companies are valued based upon their reported NAVs, or NAV per share practical expedient, as applicable.
- Derivative contracts listed on exchanges are valued at their reported settlement or closing price, except that options are valued at the mean of closing bid and ask quotations.
- Over-the-counter (OTC) derivative contracts are fair valued using price evaluations provided by a pricing service approved by the Adviser.
- For securities that are fair valued in accordance with procedures established by and under the general supervision of the Adviser, certain factors may be considered, such as: the last traded or purchase price of the security, information obtained by contacting the issuer or dealers, analysis of the issuer's financial statements or other available documents, fundamental analytical data, the nature and duration of restrictions on disposition, the movement of the market in which the security is normally traded, public trading in similar securities or derivative contracts of the issuer or comparable issuers, movement of a relevant index, or other factors including but not limited to industry changes and relevant government actions.

If any price, quotation, price evaluation or other pricing source is not readily available when the NAV is calculated, if the Fund cannot obtain price evaluations from a pricing service or from more than one dealer for an investment within a reasonable period of time as set forth in the Adviser's valuation policies and procedures for the Fund, or if information furnished by a pricing service, in the opinion of the Adviser's valuation committee ("Valuation Committee"), is deemed not representative of the fair value of such security, the Fund uses the fair value of the investment determined in accordance with the procedures described below. There can be no assurance that the Fund could obtain the fair value assigned to an investment if it sold the investment at approximately the time at which the Fund determines its NAV per share, and the actual value obtained could be materially different.

### Fair Valuation and Significant Events Procedures

Pursuant to Rule 2a-5 under the Act, the Fund's Board of Trustees (the "Trustees") has designated the Adviser as the Fund's valuation designee to perform any fair value determinations for securities and other assets held by the Fund. The Adviser is subject to the Trustees' oversight and certain reporting and other requirements intended to provide the Trustees the information needed to oversee the Adviser's fair value determinations.

The Adviser, acting through its Valuation Committee, is responsible for determining the fair value of investments for which market quotations are not readily available. The Valuation Committee is comprised of officers of the Adviser and certain of the Adviser's affiliated companies and determines fair value and oversees the calculation of the NAV. The Valuation Committee is also authorized to use pricing services to provide fair value evaluations of the current value of certain investments for purposes of calculating the NAV. The Valuation Committee employs various methods for reviewing third-party pricing-service evaluations including periodic reviews of third-party pricing services' policies, procedures and valuation methods (including key inputs, methods, models and assumptions), transactional back-testing, comparisons of evaluations of different pricing services, and review of price challenges by the Adviser based on recent market activity. In the event that market quotations and price evaluations are not available for an investment, the Valuation Committee determines the fair value of the investment in accordance with procedures adopted by the Adviser. The Trustees periodically review the fair valuations made by the Valuation Committee. The Trustees have also approved the Adviser's fair valuation and significant events procedures as part of the Fund's compliance program and will review any changes made to the procedures.

Factors considered by pricing services in evaluating an investment include the yields or prices of investments of comparable quality, coupon, maturity, call rights and other potential prepayments, terms and type, reported transactions, indications as to values from dealers and general market conditions. Some pricing services provide a single price evaluation reflecting the bid-side of the market for an investment (a "bid" evaluation). Other pricing services offer both bid evaluations and price evaluations indicative of a price between

the prices bid and ask for the investment (a “mid” evaluation). The Fund normally uses bid evaluations for any U.S. Treasury and Agency securities, mortgage-backed securities and municipal securities. The Fund normally uses mid evaluations for any other types of fixed-income securities and any OTC derivative contracts. In the event that market quotations and price evaluations are not available for an investment, the fair value of the investment is determined in accordance with procedures adopted by the Adviser.

The Adviser has also adopted procedures requiring an investment to be priced at its fair value whenever the Valuation Committee determines that a significant event affecting the value of the investment has occurred between the time as of which the price of the investment would otherwise be determined and the time as of which the NAV is computed. An event is considered significant if there is both an affirmative expectation that the investment’s value will change in response to the event and a reasonable basis for quantifying the resulting change in value. Examples of significant events that may occur after the close of the principal market on which a security is traded, or after the time of a price evaluation provided by a pricing service or a dealer, include:

- With respect to securities traded principally in foreign markets, significant trends in U.S. equity markets or in the trading of foreign securities index futures contracts;
- Political or other developments affecting the economy or markets in which an issuer conducts its operations or its securities are traded;
- Announcements concerning matters such as acquisitions, recapitalizations, litigation developments, or a natural disaster affecting the issuer’s operations or regulatory changes or market developments affecting the issuer’s industry.

The Adviser has adopted procedures whereby the Valuation Committee uses a pricing service to provide factors to update the fair value of equity securities traded principally in foreign markets from the time of the close of their respective foreign stock exchanges to the pricing time of the Fund. For other significant events, the Fund may seek to obtain more current quotations or price evaluations from alternative pricing sources. If a reliable alternative pricing source is not available, the Valuation Committee will determine the fair value of the investment in accordance with the fair valuation procedures approved by the Adviser. The Trustees periodically review fair valuations made in response to significant events.

### **Repurchase Agreements**

The Fund may invest in repurchase agreements for short-term liquidity purposes. It is the policy of the Fund to require the other party to a repurchase agreement to transfer to the Fund’s custodian or sub-custodian eligible securities or cash with a market value (after transaction costs) at least equal to the repurchase price to be paid under the repurchase agreement. The eligible securities are transferred to accounts with the custodian or sub-custodian in which the Fund holds a “securities entitlement” and exercises “control” as those terms are defined in the Uniform Commercial Code. The Fund has established procedures for monitoring the market value of the transferred securities and requiring the transfer of additional eligible securities if necessary to equal at least the repurchase price. These procedures also allow the other party to require securities to be transferred from the account to the extent that their market value exceeds the repurchase price or in exchange for other eligible securities of equivalent market value.

The insolvency of the other party or other failure to repurchase the securities may delay the disposition of the underlying securities or cause the Fund to receive less than the full repurchase price. Under the terms of the repurchase agreement, any amounts received by the Fund in excess of the repurchase price and related transaction costs must be remitted to the other party.

The Fund may enter into repurchase agreements in which eligible securities are transferred into joint trading accounts maintained by the custodian or sub-custodian for investment companies and other clients advised by the Fund’s Adviser and its affiliates. The Fund will participate on a pro rata basis with the other investment companies and clients in its share of the securities transferred under such repurchase agreements and in its share of proceeds from any repurchase or other disposition of such securities.

Repurchase agreements are subject to Master Netting Agreements (MNA) which are agreements between the Fund and its counterparties that provide for the net settlement of all transactions and collateral with the Fund, through a single payment, in the event of default or termination. Amounts presented on the Portfolio of Investments and Statement of Assets and Liabilities are not net settlement amounts but gross. As indicated above, the cash or securities to be repurchased, as shown on the Portfolio of Investments, exceeds the repurchase price to be paid under the agreement reducing the net settlement amount to zero.

### **Investment Income, Gains and Losses, Expenses and Distributions**

Investment transactions are accounted for on a trade-date basis. Realized gains and losses from investment transactions are recorded on an identified-cost basis. Interest income and expenses are accrued daily. Dividend income and distributions to shareholders are recorded on the ex-dividend date. Foreign dividends are recorded on the ex-dividend date or when the Fund is informed of the ex-dividend date. Amortization/accretion of premium and discount is included in investment income. Distributions of net investment income, if any, are declared and paid annually. Non-cash dividends included in dividend income, if any, are recorded at fair value. Investment income, realized and unrealized gains and losses, and certain fund-level expenses are allocated to each class based on relative average daily net assets, except that select classes will bear certain expenses unique to those classes. Dividends are declared separately for each class. No class has preferential dividend rights; differences in per share dividend rates are generally due to differences in separate class expenses. The detail of the total fund expense waiver of \$1,648 is disclosed in Note 5.

### **Federal Taxes**

It is the Fund’s policy to comply with the Subchapter M provision of the Internal Revenue Code of 1986 (the “Code”) and to distribute to shareholders each year substantially all of its income. Accordingly, no provision for federal income tax is necessary. As of and during the year ended December 31, 2022, the Fund did not have a liability for any uncertain tax positions. The Fund recognizes interest and penalties, if any, related to tax liabilities as income tax expense in the Statement of Operations. As of December 31, 2022, tax years 2019 through 2022 remain subject to examination by the Fund’s major tax jurisdictions, which include the United States of America and the Commonwealth of Massachusetts.

The Fund may be subject to taxes imposed by governments of countries in which it invests. Such taxes are generally based on either income or gains earned or repatriated. The Fund accrues and applies such taxes to net investment income, net realized gains and net unrealized gains as income and/or gains are earned.

### **When-Issued and Delayed-Delivery Transactions**

The Fund may engage in when-issued or delayed-delivery transactions. The Fund records when-issued securities on the trade date and maintains security positions such that sufficient liquid assets will be available to make payment for the securities purchased. Securities purchased on a when-issued or delayed-delivery basis are marked to market daily and begin earning interest on the settlement date. Losses may occur on these transactions due to changes in market conditions or the failure of counterparties to perform under the contract.

### **Futures Contracts**

The Fund purchases and sells financial futures contracts to manage currency risk and market risks. Upon entering into a financial futures contract with a broker, the Fund is required to deposit with a broker, either U.S. government securities or a specified amount of cash, which is shown as due from broker in the Statement of Assets and Liabilities. Futures contracts are valued daily and unrealized gains or losses are recorded in a "variation margin" account. The Fund receives from or pays to the broker a specified amount of cash based upon changes in the variation margin account. When a contract is closed, the Fund recognizes a realized gain or loss. Futures contracts have market risks, including the risk that the change in the value of the contract may not correlate with the changes in the value of the underlying securities. There is minimal counterparty risk to the Fund since futures contracts are exchange traded and the exchange's clearing house, as counterparty to all exchange traded futures contracts, guarantees the futures contracts against default.

During the year ended December 31, 2022, the Fund held no futures contracts.

### **Foreign Exchange Contracts**

The Fund enters into foreign exchange contracts for the delayed-delivery of securities or foreign currency exchange transactions. The Fund also enters into foreign exchange contracts to protect assets against adverse changes in foreign currency exchange rates or exchange control regulations. Purchased contracts are used to acquire exposure to foreign currencies, whereas, contracts to sell are used to hedge the Fund's securities against currency fluctuations. Risks may arise upon entering into these transactions from the potential inability of counterparties to meet the terms of their commitments and from unanticipated movements in security prices or foreign exchange rates. The foreign exchange contracts are adjusted by the daily exchange rate of the underlying currency and any gains or losses are recorded for financial statement purposes as unrealized until the settlement date.

During the year ended December 31, 2022, the Fund held no foreign exchange contracts.

### **Foreign Currency Translation**

The accounting records of the Fund are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rates of exchange of such currencies against U.S. dollars on the date of valuation. Purchases and sales of securities, income and expenses are translated at the rate of exchange quoted on the respective date that such transactions are recorded. The Fund does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations are included with the net realized and unrealized gain or loss from investments.

Reported net realized foreign exchange gains or losses arise from sales of foreign currencies, currency gains or losses realized between the trade and settlement dates on securities transactions, the difference between the amounts of dividends, interest and foreign withholding taxes recorded on the Fund's books, and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains and losses arise from changes in the value of assets and liabilities other than investments in securities at period end, resulting from changes in the exchange rate.

### **Securities Lending**

The Fund participates in a securities lending program providing for the lending of equity securities to qualified brokers. The term of the loans within the program is one year or less. The Fund normally receives cash collateral for securities loaned that is invested in affiliated money market funds, other money market instruments and/or repurchase agreements. Investments in money market funds may include funds with a "floating" NAV that can impose redemption fees and liquidity gates, impose certain operational impediments to investing cash collateral, and, if the investee fund's NAV decreases, result in the Fund recognizing losses and being required to cover the decrease in the value of the cash collateral. Collateral is maintained at a minimum level of 100% of the market value of investments loaned, plus interest, if applicable. In accordance with the Fund's securities lending agreement, the market value of securities on loan is determined each day at the close of business and any additional collateral required to cover the value of securities on loan is delivered to the Fund on the next business day. Earnings on collateral are allocated between the borrower of the security, the securities lending agent, as a fee for its services under the program and the Fund, according to agreed-upon rates. The Fund will not have the right to vote on securities while they are on loan. However, the Fund will attempt to terminate a loan in an effort to reacquire the securities in time to vote on matters that are deemed to be material by the Adviser. There can be no assurance that the Fund will have sufficient notice of such matters to be able to terminate the loan in time to vote thereon.

Securities lending transactions are subject to MNA. Amounts presented on the Portfolio of Investments and Statement of Assets and Liabilities are not net settlement amounts but gross. As indicated below, the cash collateral received by the Fund exceeds the market value of the securities loaned reducing the net settlement amount to zero. The chart below identifies the amount of collateral received as well as the market value of securities on loan. Additionally, the securities lending agreement executed by the Fund includes an indemnification clause. This clause stipulates that the borrower will reimburse the Fund for any losses as a result of any failure of the borrower to return equivalent securities to the Fund.

As of December 31, 2022, securities subject to this type of arrangement and related collateral were as follows:

Fair Value of Securities Loaned	Collateral Received
\$368,981	\$388,239

### Restricted Securities

The Fund may purchase securities which are considered restricted. Restricted securities are securities that either: (a) cannot be offered for public sale without first being registered, or being able to take advantage of an exemption from registration, under the Securities Act of 1933; or (b) are subject to contractual restrictions on public sales. In some cases, when a security cannot be offered for public sale without first being registered, the issuer of the restricted security has agreed to register such securities for resale, at the issuer's expense, either upon demand by the Fund or in connection with another registered offering of the securities. Many such restricted securities may be resold in the secondary market in transactions exempt from registration. Restricted securities may be determined to be liquid under criteria established by the Trustees. The Fund will not incur any registration costs upon such resales. The Fund's restricted securities, like other securities, are priced in accordance with procedures established by and under the general supervision of the Adviser.

Additional information on restricted securities, held at December 31, 2022, is as follows:

Security	Acquisition Date	Cost	Value
Immatic N.V.	6/30/2020	\$100,000	\$87,100

### Other

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, expenses and revenues reported in the financial statements. Actual results could differ materially from those estimated. The Fund applies investment company accounting and reporting guidance.

### 3. SHARES OF BENEFICIAL INTEREST

The following tables summarize share activity:

	Year Ended 12/31/2022		Year Ended 12/31/2021	
	Shares	Amount	Shares	Amount
<b>Primary Shares:</b>				
Shares sold	126,871	\$ 2,146,304	79,728	\$ 1,955,393
Shares issued to shareholders in payment of distributions declared	277,971	5,000,705	177,614	4,188,147
Shares redeemed	(402,248)	(6,715,513)	(474,074)	(11,765,919)
NET CHANGE RESULTING FROM PRIMARY SHARE TRANSACTIONS	2,594	\$ 431,496	(216,732)	\$ (5,622,379)

	Year Ended 12/31/2022		Year Ended 12/31/2021	
	Shares	Amount	Shares	Amount
<b>Service Shares:</b>				
Shares sold	1,893,686	\$ 28,555,074	1,311,017	\$ 29,782,483
Shares issued to shareholders in payment of distributions declared	928,534	15,209,380	564,549	12,290,239
Shares redeemed	(1,623,969)	(24,958,839)	(2,283,278)	(52,342,855)
NET CHANGE RESULTING FROM SERVICE SHARE TRANSACTIONS	1,198,251	\$ 18,805,615	(407,712)	\$(10,270,133)
NET CHANGE RESULTING FROM TOTAL FUND SHARE TRANSACTIONS	1,200,845	\$ 19,237,111	(624,444)	\$(15,892,512)

### 4. FEDERAL TAX INFORMATION

The accounting treatment of certain items in accordance with income tax regulations may differ from the accounting treatment in accordance with GAAP which may result in permanent differences. In the case of the Fund, such differences primarily result from net operating losses.

For the year ended December 31, 2022, permanent differences identified and reclassified among the components of net assets were as follows:

	Increase (Decrease)	Total Distributable Earnings (Loss)
<b>Paid-In Capital</b>		
\$(1,236,369)		\$1,236,369

The tax character of distributions as reported on the Statement of Changes in Net Assets for the years ended December 31, 2022 and 2021, was as follows:

	2022	2021
Long-term capital gains	\$20,210,101	\$16,478,398

As of December 31, 2022, the components of distributable earnings on a tax-basis were as follows:

Net unrealized appreciation	\$35,340,771
Capital loss carryforwards	\$ (721,039)
<b>TOTAL</b>	<b>\$34,619,732</b>

At December 31, 2022, the cost of investments for federal tax purposes was \$109,373,174. The net unrealized appreciation of investments for federal tax purposes was \$35,340,985. This consists of net unrealized appreciation from investments for those securities having an excess of value over cost of \$45,537,742 and net unrealized depreciation from investments for those securities having an excess of cost over value of \$10,196,757. The difference between book-basis and tax-basis net unrealized appreciation is attributable to differing treatments for deferral of losses on wash sales, passive foreign investment company adjustments and discount accretion/premium amortization on debt securities.

As of December 31, 2022, the Fund had a capital loss carryforward of \$721,039 which will reduce the Fund's taxable income arising from future net realized gains on investments, if any, to the extent permitted by the Code, thereby reducing the amount of distributions to shareholders which would otherwise be necessary to relieve the Fund of any liability for federal income tax. Pursuant to the Code, these net capital losses retain their character as either short-term or long-term and do not expire.

The following schedule summarizes the Fund's capital loss carryforwards:

Short-Term	Long-Term	Total
\$721,039	\$—	\$721,039

## 5. INVESTMENT ADVISER FEE AND OTHER TRANSACTIONS WITH AFFILIATES

### Investment Adviser Fee

The advisory agreement between the Fund and the Adviser provides for an annual fee equal to 1.30% of the Fund's average daily net assets. The Adviser may voluntarily choose to waive any portion of its fee and/or reimburse certain operating expenses of the Fund for competitive reasons such as to maintain the Fund's expense ratio, or as and when appropriate, to maintain positive or zero net yields. For the year ended December 31, 2022, the Adviser voluntarily waived \$1,648 of its fee.

Certain of the Fund's assets are managed by Federated Global Investment Management Corp. (the "Sub-Adviser"). Under the terms of a sub-advisory agreement between the Adviser and the Sub-Adviser, the Sub-Adviser receives an allocable portion of the Fund's adviser fee. The fee is paid by the Adviser out of its resources and is not an incremental Fund expense. For the year ended December 31, 2022, the Sub-Adviser earned a fee of \$1,659,037.

### Administrative Fee

Federated Administrative Services (FAS), under the Administrative Services Agreement, provides the Fund with administrative personnel and services. For purposes of determining the appropriate rate breakpoint, "Investment Complex" is defined as all of the Federated Hermes Funds subject to a fee under the Administrative Services Agreement. The fee paid to FAS is based on the average daily net assets of the Investment Complex as specified below:

Administrative Fee	Average Daily Net Assets of the Investment Complex
0.100%	on assets up to \$50 billion
0.075%	on assets over \$50 billion

FAS may voluntarily choose to waive any portion of its fee. For the year ended December 31, 2022, the annualized fee paid to FAS was 0.079% of average daily net assets of the Fund.

In addition, FAS may charge certain out-of-pocket expenses to the Fund.

## Distribution Services Fee

The Fund has adopted a Distribution Plan (the "Plan") pursuant to Rule 12b-1 under the Act. Under the terms of the Plan, the Fund will compensate Federated Securities Corp. (FSC), the principal distributor, from the daily net assets of the Fund's Primary Shares and Service Shares to finance activities intended to result in the sale of these shares. The Plan provides that the Fund may incur distribution expenses at the following percentages of average daily net assets annually, to compensate FSC:

	Percentage of Average Daily Net Assets of Class
Primary Shares	0.25%
Service Shares	0.25%

FSC may voluntarily choose to waive any portion of its fee. For the year ended December 31, 2022, distribution services fees for the Fund were as follows:

	Distribution Services Fees Incurred
Service Shares	\$289,503

When FSC receives fees, it may pay some or all of them to financial intermediaries whose customers purchase shares. For the year ended December 31, 2022, FSC retained \$268 of fees paid by the Fund. For the year ended December 31, 2022, the Fund's Primary Shares did not incur a distribution services fee; however, it may begin to incur this fee upon approval of the Trustees.

## Interfund Transactions

During the year ended December 31, 2022, the Fund engaged in purchase and sale transactions with funds that have a common investment adviser (or affiliated investment advisers), common Directors/Trustees and/or common Officers. These purchase and sale transactions complied with Rule 17a-7 under the Act and amounted to \$445,707 and \$567,897, respectively. Net realized loss recognized on these transactions was \$133,139.

## Directors'/Trustees' and Miscellaneous Fees

Certain Officers and Trustees of the Fund are Officers and Directors or Trustees of certain of the above companies. To efficiently facilitate payment, Independent Directors'/Trustees' fees and certain expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses are paid by an affiliate of the Adviser which in due course are reimbursed by the Fund. These expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses may be included in Accrued and Miscellaneous Expenses on the Statement of Assets and Liabilities and Statement of Operations, respectively.

## 6. INVESTMENT TRANSACTIONS

Purchases and sales of investments, excluding long-term U.S. government securities and short-term obligations, for the year ended December 31, 2022, were as follows:

Purchases	\$49,034,759
Sales	\$71,871,112

## 7. CONCENTRATION OF RISK

The Fund may invest a portion of its assets in securities of companies that are deemed by the Fund's management to be classified in similar business sectors. Economic developments may have an effect on the liquidity and volatility of the portfolio securities. A substantial portion of the Fund's portfolio may be comprised of entities in the Health Care sector. As a result, the Fund may be more susceptible to any economic, business, political or other developments which generally affect these entities.

## 8. LINE OF CREDIT

The Fund participates with certain other Federated Hermes Funds, on a several basis, in an up to \$500,000,000 unsecured, 364-day, committed, revolving line of credit (LOC) agreement dated June 22, 2022. The LOC was made available to temporarily finance the repurchase or redemption of shares of the Fund, failed trades, payment of dividends, settlement of trades and for other short-term, temporary or emergency general business purposes. The Fund cannot borrow under the LOC if an inter-fund loan is outstanding. The Fund's ability to borrow under the LOC also is subject to the limitations of the Act and various conditions precedent that must be satisfied before the Fund can borrow. Loans under the LOC are charged interest at a fluctuating rate per annum equal to (a) the highest, on any day, of (i) the federal funds effective rate, (ii) the published secured overnight financing rate plus an assigned percentage, and (iii) 0.0%, plus (b) a margin. Any fund eligible to borrow under the LOC pays its pro rata share of a commitment fee based on the amount of the lenders' commitment that has not been utilized, quarterly in arrears and at maturity. As of December 31, 2022, the Fund had no outstanding loans. During the year ended December 31, 2022, the Fund did not utilize the LOC.

## **9. INTERFUND LENDING**

Pursuant to an Exemptive Order issued by the Securities and Exchange Commission, the Fund, along with other funds advised by subsidiaries of Federated Hermes, Inc., may participate in an interfund lending program. This program provides an alternative credit facility allowing the Fund to borrow from other participating affiliated funds. As of December 31, 2022, there were no outstanding loans. During the year ended December 31, 2022, the program was not utilized.

## **10. INDEMNIFICATIONS**

Under the Fund's organizational documents, its Officers and Directors/Trustees are indemnified against certain liabilities arising out of the performance of their duties to the Fund (other than liabilities arising out of their willful misfeasance, bad faith, gross negligence or reckless disregard of their duties to the Fund). In addition, in the normal course of business, the Fund provides certain indemnifications under arrangements with third parties. Typically, obligations to indemnify a third party arise in the context of an arrangement entered into by the Fund under which the Fund agrees to indemnify such third party for certain liabilities arising out of actions taken pursuant to the arrangement, provided the third party's actions are not deemed to have breached an agreed-upon standard of care (such as willful misfeasance, bad faith, gross negligence or reckless disregard of their duties under the contract). The Fund's maximum exposure under these arrangements is unknown as this would involve future claims that may be made against the Fund that have not yet arisen. The Fund does not anticipate any material claims or losses pursuant to these arrangements at this time, and accordingly expects the risk of loss to be remote.

## **11. OTHER MATTERS**

An outbreak of respiratory disease caused by a novel coronavirus was first detected in China in late 2019 and subsequently spread globally. As of the date of the issuance of these financial statements, this coronavirus has resulted in, and may continue to result in, closed borders, enhanced health screenings, disruptions to healthcare service preparation and delivery, quarantines, cancellations, and disruptions to supply chains, workflow operations and consumer activity, as well as general concern and uncertainty. The impact of this coronavirus has resulted in substantial economic volatility. Health crises caused by outbreaks, such as the coronavirus outbreak, may exacerbate other pre-existing political, social and economic risks. The impact of this outbreak, and other epidemics and pandemics that may arise in the future, could continue to negatively affect the worldwide economy, as well as the economies of individual countries, individual companies (including certain Fund service providers and issuers of the Fund's investments) and the markets in general in significant and unforeseen ways. In addition, governments, their regulatory agencies, or self-regulatory organizations may take actions in response to the pandemic, including significant fiscal and monetary policy changes, that may affect the instruments in which the Fund invests or the issuers of such investments. Any such impact could adversely affect the Fund's performance.

## **12. FEDERAL TAX INFORMATION (UNAUDITED)**

For the year ended December 31, 2022, the amount of long-term capital gains designated by the Fund was \$20,210,101.

# Report of Independent Registered Public Accounting Firm

## TO THE BOARD OF TRUSTEES OF FEDERATED HERMES INSURANCE SERIES AND THE SHAREHOLDERS OF FEDERATED HERMES KAUFMANN FUND II:

### Opinion on the Financial Statements

We have audited the accompanying statement of assets and liabilities of Federated Hermes Kaufmann Fund II (the Fund), a portfolio of Federated Hermes Insurance Series, including the portfolio of investments, as of December 31, 2022, the related statement of operations for the year then ended, the statements of changes in net assets for each of the years in the two-year period then ended, and the related notes (collectively, the financial statements) and the financial highlights for each of the years in the five-year period then ended. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Fund as of December 31, 2022, the results of its operations for the year then ended, the changes in its net assets for each of the years in the two-year period then ended, and the financial highlights for each of the years in the five-year period then ended, in conformity with U.S. generally accepted accounting principles.

### Basis for Opinion

These financial statements and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Such procedures also included confirmation of securities owned as of December 31, 2022, by correspondence with custodians and brokers; when replies were not received from brokers, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. We believe that our audits provide a reasonable basis for our opinion.

**KPMG LLP**

We have served as the auditor for one or more of Federated Hermes' investment companies since 2006.

Boston, Massachusetts  
February 15, 2023



## Shareholder Expense Example (unaudited)

As a shareholder of the Fund, you incur ongoing costs, including management fees and to the extent applicable, distribution (12b-1) fees and/or other service fees and other Fund expenses. This Example is intended to help you to understand your ongoing costs (in dollars) of investing in the Fund and to compare these costs with the ongoing costs of investing in other funds used as variable investment options. It is based on an investment of \$1,000 invested at the beginning of the period and held for the entire period from July 1, 2022 to December 31, 2022.

### ACTUAL EXPENSES

The first section of the table below provides information about actual account values and actual expenses. You may use the information in this section, together with the amount you invested, to *estimate* the expenses that you incurred over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number in the first section under the heading entitled “Expenses Paid During Period” to estimate the expenses attributable to your investment during this period.

### HYPOTHETICAL EXAMPLE FOR COMPARISON PURPOSES

The second section of the table below provides information about hypothetical account values and hypothetical expenses based on the Fund’s actual expense ratio and an *assumed* rate of return of 5% per year before expenses, which is not the Fund’s actual return. Thus, you should *not* use the hypothetical account values and expenses to estimate the actual ending account balance or your expenses for the period. Rather, these figures are required to be provided to enable you to compare the ongoing costs of investing in the Fund with other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only. Therefore, the second section of the table is useful in comparing ongoing costs only, and will not help you determine the relative *total* costs of owning different funds.

	Beginning Account Value 7/1/2022	Ending Account Value 12/31/2022	Expenses Paid During Period <sup>1</sup>
<b>Actual:</b>			
Primary Shares	\$1,000	\$1,020.30	\$7.79
Service Shares	\$1,000	\$1,019.30	\$9.06
<b>Hypothetical (assuming a 5% return before expenses):</b>			
Primary Shares	\$1,000	\$1,017.49	\$7.78
Service Shares	\$1,000	\$1,016.23	\$9.05

<sup>1</sup> Expenses are equal to the Fund’s annualized net expense ratios, multiplied by the average account value over the period, multiplied by 184/365 (to reflect the one-half-year period). The expenses shown in the table do not include the charges and expenses imposed by the insurance company under the variable insurance product contract. Please refer to the variable insurance product prospectus for a complete listing of these expenses. The annualized net expense ratios are as follows:

Primary Shares	1.53%
Service Shares	1.78%

## Board of Trustees and Trust Officers

The Board of Trustees is responsible for managing the Trust's business affairs and for exercising all the Trust's powers except those reserved for the shareholders. The following tables give information about each Trustee and the senior officers of the Fund. Where required, the tables separately list Trustees who are "interested persons" of the Fund (i.e., "Interested" Trustees) and those who are not (i.e., "Independent" Trustees). Unless otherwise noted, the address of each person listed is 1001 Liberty Avenue, Pittsburgh, PA 15222-3779. The address of all Independent Trustees listed is 4000 Ericsson Drive, Warrendale, PA 15086-7561; Attention: Mutual Fund Board. As of December 31, 2022, the Trust comprised six portfolio(s), and the Federated Hermes Fund Family consisted of 33 investment companies (comprising 102 portfolios). Unless otherwise noted, each Officer is elected annually. Unless otherwise noted, each Trustee oversees all portfolios in the Federated Hermes Fund Family and serves for an indefinite term. The Fund's Statement of Additional Information includes additional information about Trust Trustees and is available, without charge and upon request, by calling 1-800-341-7400, Option #4.

### INTERESTED TRUSTEES BACKGROUND

Name Birth Date Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held and Previous Position(s)
<b>J. Christopher Donahue*</b> Birth Date: April 11, 1949 TRUSTEE Indefinite Term Began serving: September 1993	<b>Principal Occupations:</b> Principal Executive Officer and President of certain of the Funds in the Federated Hermes Fund Family; Director or Trustee of the Funds in the Federated Hermes Fund Family; President, Chief Executive Officer and Director, Federated Hermes, Inc.; Chairman and Trustee, Federated Investment Management Company; Trustee, Federated Investment Counseling; Chairman and Director, Federated Global Investment Management Corp.; Chairman and Trustee, Federated Equity Management Company of Pennsylvania; Trustee, Federated Shareholder Services Company; Director, Federated Services Company.  <b>Previous Positions:</b> President, Federated Investment Counseling; President and Chief Executive Officer, Federated Investment Management Company, Federated Global Investment Management Corp. and Passport Research, Ltd; Chairman, Passport Research, Ltd.
<b>Thomas R. Donahue*</b> Birth Date: October 20, 1958 TRUSTEE Indefinite Term Began serving: May 2016	<b>Principal Occupations:</b> Director or Trustee of certain of the funds in the Federated Hermes Fund Family; Chief Financial Officer, Treasurer, Vice President and Assistant Secretary, Federated Hermes, Inc.; Chairman and Trustee, Federated Administrative Services; Chairman and Director, Federated Administrative Services, Inc.; Trustee and Treasurer, Federated Advisory Services Company; Director or Trustee and Treasurer, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Counseling, and Federated Investment Management Company; Director, MDTA LLC; Director, Executive Vice President and Assistant Secretary, Federated Securities Corp.; Director or Trustee and Chairman, Federated Services Company and Federated Shareholder Services Company; and Director and President, FII Holdings, Inc.  <b>Previous Positions:</b> Director, Federated Hermes, Inc.; Assistant Secretary, Federated Investment Management Company, Federated Global Investment Management Company and Passport Research, LTD; Treasurer, Passport Research, LTD; Executive Vice President, Federated Securities Corp.; and Treasurer, FII Holdings, Inc.

\* Family relationships and reasons for "interested" status: J. Christopher Donahue and Thomas R. Donahue are brothers. Both are "interested" due to their beneficial ownership of shares of Federated Hermes, Inc. and the positions they hold with Federated Hermes, Inc. and its subsidiaries.

### INDEPENDENT TRUSTEES BACKGROUND

Name Birth Date Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
<b>John T. Collins</b> Birth Date: January 24, 1947 TRUSTEE Indefinite Term Began serving: October 2013	<b>Principal Occupations:</b> Director or Trustee, and Chair of the Board of Directors or Trustees, of the Federated Hermes Fund Family; formerly, Chairman and CEO, The Collins Group, Inc. (a private equity firm) (Retired).  <b>Other Directorships Held:</b> Director, KLX Energy Services Holdings, Inc. (oilfield services); former Director of KLX Corp. (aerospace).  <b>Qualifications:</b> Mr. Collins has served in several business and financial management roles and directorship positions throughout his career. Mr. Collins previously served as Chairman and CEO of The Collins Group, Inc. (a private equity firm) and as a Director of KLX Corp. Mr. Collins serves as Chairman Emeriti, Bentley University. Mr. Collins previously served as Director and Audit Committee Member, Bank of America Corp.; Director, FleetBoston Financial Corp.; and Director, Beth Israel Deaconess Medical Center (Harvard University Affiliate Hospital).

Name Birth Date Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
<b>G. Thomas Hough</b> Birth Date: February 28, 1955 TRUSTEE Indefinite Term Began serving: August 2015	<p><b>Principal Occupations:</b> Director or Trustee, Chair of the Audit Committee of the Federated Hermes Fund Family; formerly, Vice Chair, Ernst &amp; Young LLP (public accounting firm) (Retired).</p> <p><b>Other Directorships Held:</b> Director, Chair of the Audit Committee, Equifax, Inc.; Lead Director, Member of the Audit and Nominating and Corporate Governance Committees, Haverty Furniture Companies, Inc.; formerly, Director, Member of Governance and Compensation Committees, Publix Super Markets, Inc.</p> <p><b>Qualifications:</b> Mr. Hough has served in accounting, business management and directorship positions throughout his career. Mr. Hough most recently held the position of Americas Vice Chair of Assurance with Ernst &amp; Young LLP (public accounting firm). Mr. Hough serves on the President's Cabinet and Business School Board of Visitors for the University of Alabama. Mr. Hough previously served on the Business School Board of Visitors for Wake Forest University, and he previously served as an Executive Committee member of the United States Golf Association.</p>
<b>Maureen Lally-Green</b> Birth Date: July 5, 1949 TRUSTEE Indefinite Term Began serving: August 2009	<p><b>Principal Occupations:</b> Director or Trustee of the Federated Hermes Fund Family; Adjunct Professor Emerita of Law, Duquesne University School of Law; formerly, Dean of the Duquesne University School of Law and Professor of Law and Interim Dean of the Duquesne University School of Law; formerly, Associate General Secretary and Director, Office of Church Relations, Diocese of Pittsburgh.</p> <p><b>Other Directorships Held:</b> Director, CNX Resources Corporation (natural gas).</p> <p><b>Qualifications:</b> Judge Lally-Green has served in various legal and business roles and directorship positions throughout her career. Judge Lally-Green previously held the position of Dean of the School of Law of Duquesne University (as well as Interim Dean). Judge Lally-Green previously served as Associate General Secretary of the Diocese of Pittsburgh, a member of the Superior Court of Pennsylvania and as a Professor of Law, Duquesne University School of Law. Judge Lally-Green was appointed by the Supreme Court of Pennsylvania to serve on the Supreme Court's Board of Continuing Judicial Education and the Supreme Court's Appellate Court Procedural Rules Committee. Judge Lally-Green also currently holds the positions on not for profit or for profit boards of directors as follows: Director and Chair, UPMC Mercy Hospital; Regent, Saint Vincent Seminary; Member, Pennsylvania State Board of Education (public); Director, Catholic Charities, Pittsburgh; and Director CNX Resources Corporation (natural gas). Judge Lally-Green has held the positions of: Director, Auberle; Director, Epilepsy Foundation of Western and Central Pennsylvania; Director, Ireland Institute of Pittsburgh; Director, Saint Thomas More Society; Director and Chair, Catholic High Schools of the Diocese of Pittsburgh, Inc.; Director, Pennsylvania Bar Institute; Director, St. Vincent College; Director and Chair, North Catholic High School, Inc.; Director and Vice Chair, Our Campaign for the Church Alive!, Inc.; and Director and Vice Chair, Saint Francis University.</p>
<b>Thomas M. O'Neill</b> Birth Date: June 14, 1951 TRUSTEE Indefinite Term Began serving: August 2006	<p><b>Principal Occupations:</b> Director or Trustee of the Federated Hermes Fund Family; Sole Proprietor, Navigator Management Company (investment and strategic consulting).</p> <p><b>Other Directorships Held:</b> None.</p> <p><b>Qualifications:</b> Mr. O'Neill has served in several business, mutual fund and financial management roles and directorship positions throughout his career. Mr. O'Neill serves as Director, Medicines for Humanity. Mr. O'Neill previously served as Chief Executive Officer and President, Managing Director and Chief Investment Officer, Fleet Investment Advisors; President and Chief Executive Officer, Aeltus Investment Management, Inc.; General Partner, Hellman, Jordan Management Co., Boston, MA; Chief Investment Officer, The Putnam Companies, Boston, MA; Credit Analyst and Lending Officer, Fleet Bank; Director and Consultant, EZE Castle Software (investment order management software); Director, Midway Pacific (lumber); and Director, The Golisano Children's Museum of Naples, Florida.</p>
<b>Madelyn A. Reilly</b> Birth Date: February 2, 1956 TRUSTEE Indefinite Term Began serving: November 2020	<p><b>Principal Occupations:</b> Director or Trustee of the Federated Hermes Fund Family; formerly, Senior Vice President for Legal Affairs, General Counsel and Secretary of Board of Directors, Duquesne University (Retired).</p> <p><b>Other Directorships Held:</b> None.</p> <p><b>Qualifications:</b> Ms. Reilly has served in various business and legal management roles throughout her career. Ms. Reilly previously served as Senior Vice President for Legal Affairs, General Counsel and Secretary of Board of Directors and Director of Risk Management and Associate General Counsel, Duquesne University. Prior to her work at Duquesne University, Ms. Reilly served as Assistant General Counsel of Compliance and Enterprise Risk as well as Senior Counsel of Environment, Health and Safety, PPG Industries. Ms. Reilly currently serves as a member of the Board of Directors of UPMC Mercy Hospital.</p>
<b>P. Jerome Richey</b> Birth Date: February 23, 1949 TRUSTEE Indefinite Term Began serving: October 2013	<p><b>Principal Occupations:</b> Director or Trustee of the Federated Hermes Fund Family; Retired; formerly, Senior Vice Chancellor and Chief Legal Officer, University of Pittsburgh and Executive Vice President and Chief Legal Officer, CONSOL Energy Inc. (now split into two separate publicly traded companies known as CONSOL Energy Inc. and CNX Resources Corp.).</p> <p><b>Other Directorships Held:</b> None.</p> <p><b>Qualifications:</b> Mr. Richey has served in several business and legal management roles and directorship positions throughout his career. Mr. Richey most recently held the positions of Senior Vice Chancellor and Chief Legal Officer, University of Pittsburgh. Mr. Richey previously served as Chairman of the Board, Epilepsy Foundation of Western Pennsylvania and Chairman of the Board, World Affairs Council of Pittsburgh. Mr. Richey previously served as Chief Legal Officer and Executive Vice President, CONSOL Energy Inc. and CNX Gas Company; and Board Member, Ethics Counsel and Shareholder, Buchanan Ingersoll &amp; Rooney PC (a law firm).</p>

Name Birth Date Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
<b>John S. Walsh</b> Birth Date: November 28, 1957 TRUSTEE Indefinite Term Began serving: January 1999	<b>Principal Occupations:</b> Director or Trustee of the Federated Hermes Fund Family; President and Director, Heat Wagon, Inc. (manufacturer of construction temporary heaters); President and Director, Manufacturers Products, Inc. (distributor of portable construction heaters); President, Portable Heater Parts, a division of Manufacturers Products, Inc.  <b>Other Directorships Held:</b> None.  <b>Qualifications:</b> Mr. Walsh has served in several business management roles and directorship positions throughout his career. Mr. Walsh previously served as Vice President, Walsh & Kelly, Inc. (paving contractors).

## OFFICERS

Name Birth Date Address Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years and Previous Position(s)
<b>Lori A. Hensler</b> Birth Date: January 6, 1967 TREASURER Officer since: April 2013	<b>Principal Occupations:</b> Principal Financial Officer and Treasurer of the Federated Hermes Fund Family; Senior Vice President, Federated Administrative Services; Financial and Operations Principal for Federated Securities Corp.; and Assistant Treasurer, Federated Investors Trust Company. Ms. Hensler has received the Certified Public Accountant designation.  <b>Previous Positions:</b> Controller of Federated Hermes, Inc.; Senior Vice President and Assistant Treasurer, Federated Investors Management Company; Treasurer, Federated Investors Trust Company; Assistant Treasurer, Federated Administrative Services, Federated Administrative Services, Inc., Federated Securities Corp., Edgewood Services, Inc., Federated Advisory Services Company, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Counseling, Federated Investment Management Company, Passport Research, Ltd., and Federated MDTA, LLC; Financial and Operations Principal for Federated Securities Corp., Edgewood Services, Inc. and Southpointe Distribution Services, Inc.
<b>Peter J. Germain</b> Birth Date: September 3, 1959 CHIEF LEGAL OFFICER, SECRETARY AND EXECUTIVE VICE PRESIDENT Officer since: January 2005	<b>Principal Occupations:</b> Mr. Germain is Chief Legal Officer, Secretary and Executive Vice President of the Federated Hermes Fund Family. He is General Counsel, Chief Legal Officer, Secretary and Executive Vice President, Federated Hermes, Inc.; Trustee and Senior Vice President, Federated Investors Management Company; Trustee and President, Federated Administrative Services; Director and President, Federated Administrative Services, Inc.; Director and Vice President, Federated Securities Corp.; Director and Secretary, Federated Private Asset Management, Inc.; Secretary, Federated Shareholder Services Company; and Secretary, Retirement Plan Service Company of America. Mr. Germain joined Federated Hermes, Inc. in 1984 and is a member of the Pennsylvania Bar Association.  <b>Previous Positions:</b> Deputy General Counsel, Special Counsel, Managing Director of Mutual Fund Services, Federated Hermes, Inc.; Senior Vice President, Federated Services Company; and Senior Corporate Counsel, Federated Hermes, Inc.
<b>John B. Fisher</b> Birth Date: May 16, 1956 PRESIDENT Officer since: November 2004	<b>Principal Occupations:</b> Principal Executive Officer and President of certain of the Funds in the Federated Hermes Fund Family; Director or Trustee of certain of the Funds in the Federated Hermes Fund Family; Director and Vice President, Federated Hermes, Inc.; President, Director/Trustee and CEO, Federated Advisory Services Company, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Counseling, Federated Investment Management Company, and Federated MDTA LLC; Director, Federated Investors Trust Company.  <b>Previous Positions:</b> President and Director of the Institutional Sales Division of Federated Securities Corp.; President and CEO of Passport Research, Ltd.; Director and President, Technology, Federated Services Company.
<b>Stephen Van Meter</b> Birth Date: June 5, 1975 CHIEF COMPLIANCE OFFICER AND SENIOR VICE PRESIDENT Officer since: July 2015	<b>Principal Occupations:</b> Senior Vice President and Chief Compliance Officer of the Federated Hermes Fund Family; Vice President and Chief Compliance Officer of Federated Hermes, Inc. and Chief Compliance Officer of certain of its subsidiaries. Mr. Van Meter joined Federated Hermes, Inc. in October 2011. He holds FINRA licenses under Series 3, 7, 24 and 66.  <b>Previous Positions:</b> Mr. Van Meter previously held the position of Compliance Operating Officer, Federated Hermes, Inc. Prior to joining Federated Hermes, Inc., Mr. Van Meter served at the United States Securities and Exchange Commission in the positions of Senior Counsel, Office of Chief Counsel, Division of Investment Management and Senior Counsel, Division of Enforcement.
<b>Stephen F. Auth</b> Birth Date: September 13, 1956 101 Park Avenue 41 <sup>st</sup> Floor New York, NY 10178 CHIEF INVESTMENT OFFICER Officer since: November 2002	<b>Principal Occupations:</b> Stephen F. Auth is Chief Investment Officer of various Funds in the Federated Hermes Fund Family; Executive Vice President, Federated Investment Counseling, Federated Global Investment Management Corp. and Federated Equity Management Company of Pennsylvania.  <b>Previous Positions:</b> Executive Vice President, Federated Investment Management Company and Passport Research, Ltd. (investment advisory subsidiary of Federated); Senior Vice President, Global Portfolio Management Services Division; Senior Vice President, Federated Investment Management Company and Passport Research, Ltd.; Senior Managing Director and Portfolio Manager, Prudential Investments.
<b>Robert J. Ostrowski</b> Birth Date: April 26, 1963 CHIEF INVESTMENT OFFICER Officer since: May 2004	<b>Principal Occupations:</b> Robert J. Ostrowski joined Federated Hermes, Inc. in 1987 as an Investment Analyst and became a Portfolio Manager in 1990. He was named Chief Investment Officer of Federated Hermes' taxable fixed-income products in 2004 and also serves as a Senior Portfolio Manager. Mr. Ostrowski became an Executive Vice President of the Fund's Adviser in 2009 and served as a Senior Vice President of the Fund's Adviser from 1997 to 2009. Mr. Ostrowski has received the Chartered Financial Analyst designation. He received his M.S. in Industrial Administration from Carnegie Mellon University.

---

Name	Birth Date	Address	Principal Occupation(s) for Past Five Years and Previous Position(s)
<b>Deborah A. Cunningham</b>	Birth Date: September 15, 1959	CHIEF INVESTMENT OFFICER Officer since: June 2012	<b>Principal Occupations:</b> Deborah A. Cunningham was named Chief Investment Officer of Federated Hermes' money market products in 2004. She joined Federated Hermes in 1981 and has been a Senior Portfolio Manager since 1997 and an Executive Vice President of the Fund's Adviser since 2009. Ms. Cunningham has received the Chartered Financial Analyst designation and holds an M.S.B.A. in Finance from Robert Morris College.

---

## Evaluation and Approval of Advisory Contract – May 2022

### **FEDERATED HERMES KAUFMANN FUND II (THE “FUND”)**

At its meetings in May 2022 (the “May Meetings”), the Fund’s Board of Trustees (the “Board”), including those Trustees who are not “interested persons” of the Fund, as defined in the Investment Company Act of 1940 (the “Independent Trustees”), reviewed and unanimously approved the continuation of the investment advisory contract between the Fund and Federated Equity Management Company of Pennsylvania (the “Adviser”) and the investment subadvisory contract between the Adviser and Federated Global Investment Management Corp. (the “Sub-Adviser” and together with the Adviser, the “Advisers”) with respect to the Fund (together, the “Contracts”) for an additional one-year term. The Board’s determination to approve the continuation of the Contracts reflects the exercise of its business judgment after considering all of the information and factors believed to be relevant and appropriate on whether to approve the continuation of the existing arrangements. The information, factors and conclusions that formed the basis for the Board’s approval are summarized below.

### **Information Received and Review Process**

At the request of the Independent Trustees, the Fund’s Chief Compliance Officer (the “CCO”) furnished to the Board in advance of its May Meetings an independent written evaluation presenting on the topics discussed below. The Board considered the CCO’s independent written evaluation (the “CCO Fee Evaluation Report”), along with other information, in evaluating the reasonableness of the Fund’s management fee and in determining to approve the continuation of the Contracts. The CCO, in preparing the CCO Fee Evaluation Report, has the authority to retain consultants, experts or staff as reasonably necessary to assist in the performance of his duties, reports directly to the Board, and can be terminated only with the approval of a majority of the Independent Trustees. At the request of the Independent Trustees, the CCO Fee Evaluation Report followed the same general approach and covered the same topics as that of the report that had previously been delivered by the CCO in his capacity as “Senior Officer” prior to the elimination of the Senior Officer position in December 2017.

In addition to the extensive materials that comprise and accompany the CCO Fee Evaluation Report, the Board considered information specifically prepared in connection with the approval of the continuation of the Contracts that was presented at the May Meetings. In this regard, in the months preceding the May Meetings, the Board requested and reviewed written responses and supporting materials prepared by the Advisers and their affiliates (collectively, “Federated Hermes”) in response to requests posed to Federated Hermes by independent legal counsel on behalf of the Independent Trustees encompassing a wide variety of topics, including those summarized below. The Board also considered such additional matters as the Independent Trustees deemed reasonably necessary to evaluate the Contracts, which included detailed information about the Fund and Federated Hermes furnished to the Board at its meetings throughout the year and in between regularly scheduled meetings on particular matters as the need arose.

The Board’s consideration of the Contracts included review of materials and information covering the following matters, among others: the nature, quality and extent of the advisory and other services provided to the Fund by the Advisers and their affiliates; Federated Hermes’ business and operations; the Advisers’ investment philosophy, personnel and processes; the Fund’s investment objectives and strategies; the Fund’s short-term and long-term performance (in absolute terms, both on a gross basis and net of expenses, and relative to the Fund’s particular investment program and a group of its peer funds and/or its benchmark, as appropriate); the Fund’s fees and expenses, including the advisory fee and the overall expense structure of the Fund (both in absolute terms and relative to a group of its peer funds), with due regard for contractual or voluntary expense limitations (if any); the financial condition of Federated Hermes; the Adviser’s profitability with respect to the Fund; distribution and sales activity for the Fund; and the use and allocation of brokerage commissions derived from trading the Fund’s portfolio securities (if any).

The Board also considered judicial decisions concerning allegedly excessive investment advisory fees charged to other registered funds in determining to approve the Contracts. Using these judicial decisions as a guide, the Board observed that the following factors may be relevant to an adviser’s fiduciary duty with respect to its receipt of compensation from a fund: (1) the nature and quality of the services provided by the adviser to the fund and its shareholders, including the performance of the fund, its benchmark and comparable funds; (2) the adviser’s cost of providing the services and the profitability to the adviser of providing advisory services to the fund; (3) the extent to which the adviser may realize “economies of scale” as the fund grows larger and, if such economies of scale exist, whether they have been appropriately shared with the fund and its shareholders or the family of funds; (4) any “fall-out” benefits that accrue to the adviser because of its relationship with the fund, including research services received from brokers that execute fund trades and any fees paid to affiliates of the adviser for services rendered to the fund; (5) comparative fee and expense structures, including a comparison of management fees paid to the adviser with those paid by similar funds both internally and externally as well as management fees charged to institutional and other advisory clients of the adviser for what might be viewed as like services; and (6) the extent of care, conscientiousness and independence with which the fund’s board

members perform their duties and their expertise, including whether they are fully informed about all facts the board deems relevant to its consideration of the adviser's services and fees. The Board noted that the Securities and Exchange Commission ("SEC") disclosure requirements regarding the basis for a fund board's approval of the fund's investment advisory contract generally align with the factors listed above. The Board was guided by these factors in its review of the Contracts to the extent it considered them to be appropriate and relevant, as discussed further below. The Board considered and weighed these factors in light of its substantial accumulated experience in governing the Fund and working with Federated Hermes on matters relating to the oversight of the other funds advised by Federated Hermes (each, a "Federated Hermes Fund" and, collectively, the "Federated Hermes Funds").

In addition to considering the above-referenced factors, the Board was mindful of the preferences and expectations of Fund shareholders and the potential disruptions of the Fund's operations and various risks, uncertainties and other effects that could occur as a result of a decision to terminate or not renew the Contracts. In particular, the Board recognized that many shareholders likely have invested in the Fund on the strength of Federated Hermes' industry standing and reputation and with the expectation that Federated Hermes will have a continuing role in providing advisory services to the Fund. Thus, the Board observed that in the marketplace there are a range of investment options available to the Fund's shareholders and such shareholders, having had the opportunity to consider other investment options, have effectively selected Federated Hermes by virtue of investing in the Fund.

In determining to approve the continuation of the Contracts, the members of the Board reviewed and evaluated information and factors they believed to be relevant and appropriate through the exercise of their reasonable business judgment. While individual members of the Board may have weighed certain factors differently, the Board's determination to approve the continuation of the Contracts was based on a comprehensive consideration of all information provided to the Board throughout the year and specifically with respect to the continuation of the Contracts. The Board recognized that its evaluation process is evolutionary and that the factors considered and emphasis placed on relevant factors may change in recognition of changing circumstances in the registered fund marketplace. The Independent Trustees were assisted throughout the evaluation process by independent legal counsel. In connection with their deliberations at the May Meetings, the Independent Trustees met separately in executive session with their independent legal counsel and without management present to review the relevant materials and consider their responsibilities under applicable laws. In addition, senior management representatives of Federated Hermes also met with the Independent Trustees and their independent legal counsel to discuss the materials and presentations furnished to the Board at the May Meetings. The Board considered the approval of the Contracts for the Fund as part of its consideration of agreements for funds across the family of Federated Hermes Funds, but its approvals were made on a fund-by-fund basis.

#### **Nature, Extent and Quality of Services**

The Board considered the nature, extent and quality of the services provided to the Fund by the Advisers and the resources of Federated Hermes dedicated to the Fund. In this regard, the Board evaluated, among other things, the terms of the Contracts and the range of services provided to the Fund by Federated Hermes. The Board considered the Advisers' personnel, investment philosophy and process, investment research capabilities and resources, trade operations capabilities, experience and performance track record. The Board reviewed the qualifications, backgrounds and responsibilities of the portfolio management team primarily responsible for the day-to-day management of the Fund and Federated Hermes' ability and experience in attracting and retaining qualified personnel to service the Fund. The Board also considered the Advisers' ability to deliver competitive investment performance for the Fund when compared to the Fund's Performance Peer Group (as defined below), which was deemed by the Board to be a useful indicator of how the Advisers are executing the Fund's investment program.

In addition, the Board considered the financial resources and overall reputation of Federated Hermes and its willingness to consider and make investments in personnel, infrastructure, technology, cybersecurity, business continuity planning and operational enhancements that are designed to benefit the Federated Hermes Funds. The Board noted the significant acquisition of Hermes Fund Managers Limited by Federated Hermes, which has deepened the organization's investment management expertise and capabilities and expanded the investment process for all of the Federated Hermes Funds to have access to analytical resources related to environmental, social and governance ("ESG") factors and issuer engagement on ESG matters. The Board considered Federated Hermes' oversight of the securities lending program for the Federated Hermes Funds that engage in securities lending and noted the income earned by the Federated Hermes Funds that participate in such program. In addition, the Board considered the quality of Federated Hermes' communications with the Board and responsiveness to Board inquiries and requests made from time to time with respect to the Fund and other Federated Hermes Funds. In this regard, the Board took into account Federated Hermes' communications with the Board in light of the pandemic. The Board also considered that Federated Hermes is responsible for providing the Federated Hermes Funds' officers.

The Board received and evaluated information regarding Federated Hermes' regulatory and compliance environment. The Board considered Federated Hermes' compliance program and compliance history and reports from the CCO about Federated Hermes' compliance with applicable laws and regulations, including responses to regulatory developments and any compliance or other issues raised by regulatory agencies. The Board also noted Federated Hermes' support of the Federated Hermes Funds' compliance control structure and the compliance-related resources devoted by Federated Hermes in support of the Fund's obligations pursuant to Rule 38a-1 under the Investment Company Act of 1940, including Federated Hermes' commitment to respond to rulemaking and other regulatory initiatives of the SEC. The Board considered Federated Hermes' approach to internal audits and risk management with respect to the Federated Hermes Funds and its day-to-day oversight of the Federated Hermes Funds' compliance with their investment objectives and policies as well as with applicable laws and regulations, noting that regulatory and other developments had over time led to an increase in the scope of Federated Hermes' oversight in this regard, including in connection with the designation of the Federated Hermes Funds' investment advisers as the administrators of the Federated Hermes Funds' liquidity risk management program.

The Board also considered the implementation of Federated Hermes' business continuity plans and recognized steps taken by Federated Hermes to continue to provide the same nature, extent and quality of services to the Federated Hermes Funds during the pandemic. In addition, the Board noted Federated Hermes' commitment to maintaining high quality systems and expending substantial resources to prepare for and respond to ongoing changes due to the market, regulatory and control environments in which the Fund and its service providers operate, including changes associated with the pandemic.

The Board considered Federated Hermes' efforts to provide shareholders in the Federated Hermes Funds with a comprehensive array of funds with different investment objectives, policies and strategies. The Board considered the expenses that Federated Hermes had incurred, as well as the entrepreneurial and other risks assumed by Federated Hermes, in sponsoring and providing on-going services to new funds to expand these opportunities for shareholders. The Board noted the benefits to shareholders of being part of the family of Federated Hermes Funds, which include the general right to exchange investments between the same class of shares without the incurrence of additional sales charges.

Based on these considerations, the Board concluded that it was satisfied with the nature, extent and quality of the services provided by the Advisers to the Fund.

#### **Fund Investment Performance**

The Board considered the investment performance of the Fund. In evaluating the Fund's investment performance, the Board considered performance results in light of the Fund's investment objective, strategies and risks. The Board considered detailed investment reports on, and the Advisers' analysis of, the Fund's performance over different time periods that were provided to the Board throughout the year and in connection with the May Meetings. These reports include, among other items, information on the Fund's gross and net returns, the Fund's investment performance compared to one or more relevant categories or groups of peer funds and the Fund's benchmark index, performance attribution information and commentary on the effect of market conditions.

The Board also reviewed comparative information regarding the performance of other registered funds in the category of peer funds selected by Morningstar, Inc. (the "Morningstar"), an independent fund ranking organization (the "Performance Peer Group"). The Board noted the CCO's view that comparisons to fund peer groups may be helpful, though not conclusive, in evaluating the performance of the Advisers in managing the Fund. The Board considered, in evaluating such comparisons, that in some cases there may be differences in the funds' objectives or investment management techniques, or the costs to implement the funds, even within the same Performance Peer Group. In this connection, the Board considered that the longevity and experience of the Fund's portfolio management team and its extensive bottom-up approach to investing may limit the utility of comparisons to other equity mutual funds.

The Fund's performance fell below the median of the Performance Peer Group for the one-year, three-year and five-year periods ended December 31, 2021. The Board discussed the Fund's performance with the Advisers and recognized the efforts being taken by the Advisers in the context of other factors considered relevant by the Board.

Based on these considerations, the Board concluded that it had continued confidence in the Advisers' overall capabilities to manage the Fund.

#### **Fund Expenses**

The Board considered the advisory fee, sub-advisory fee, and overall expense structure of the Fund and the comparative fee and expense information that had been provided in connection with the May Meetings. In this regard, the Board was presented with, and considered, information regarding the contractual advisory fee rates, total expense ratios and each element of the Fund's total expense ratio (i.e., gross and net advisory fees, administrative fees, custody fees, portfolio accounting fees and transfer agency fees) relative to an appropriate group of peer funds compiled by Federated Hermes



from the category of peer funds selected by Morningstar (the “Expense Peer Group”). The Board received a description of the methodology used to select the Expense Peer Group from the overall Morningstar category. The Board also reviewed comparative information regarding the fees and expenses of the broader group of funds in the overall Morningstar category.

While mindful that courts have cautioned against giving too much weight to comparative information concerning fees charged by other advisers for managing funds with comparable investment programs, the Board noted that it found the use of such comparisons to be relevant to its evaluation. The Board focused on comparisons with other similar registered funds more heavily than non-registered fund products or services because such comparisons are believed to be more relevant. The Board considered that other registered funds are the products most like the Fund, in that they are readily available to Fund shareholders as alternative investment vehicles, and they are the type of investment vehicle, in fact, chosen and maintained by the Fund’s shareholders. The Board noted that the range of such other registered funds’ fees and expenses, therefore, appears to be a relevant indicator of what investors have found to be reasonable in the marketplace in which the Fund competes.

The Board reviewed the contractual advisory fee rate, and other expenses of the Fund and noted the position of the Fund’s contractual advisory fee rate and other expenses relative to its Expense Peer Group. In this regard, the Board noted that the contractual advisory fee rate was above the median of the Expense Peer Group, but the Board noted the applicable waivers and reimbursements, and that the overall expense structure of the Fund remained competitive in the context of other factors considered by the Board.

The Board also received and considered information about the fees charged by Federated Hermes for providing advisory services to other types of clients with investment strategies similar to those of the Federated Hermes Funds, including non-registered fund clients (such as institutional separate accounts) and third-party unaffiliated registered funds for which any of the Advisers or their affiliates serve as sub-adviser. The Board noted the CCO’s conclusion that non-registered fund clients are inherently different products due to the following differences, among others: (i) different types of targeted investors; (ii) different applicable laws and regulations; (iii) different legal structures; (iv) different average account sizes and portfolio management techniques made necessary by different cash flows and different associated costs; (v) the time spent by portfolio managers and their teams (among other personnel across various departments, including legal, compliance and risk management) in reviewing securities pricing and fund liquidity; (vi) different administrative responsibilities; (vii) different degrees of risk associated with management; and (viii) a variety of different costs. The Board also considered information regarding the differences in the nature of the services required for Federated Hermes to manage its proprietary registered fund business versus managing a discrete pool of assets as a sub-adviser to another institution’s registered fund, noting the CCO’s view that Federated Hermes generally performs significant additional services and assumes substantially greater risks in managing the Fund and other Federated Hermes Funds than in its role as sub-adviser to an unaffiliated third-party registered fund. The Board noted that the CCO did not consider the fees for providing advisory services to other types of clients to be determinative in judging the appropriateness of the Federated Hermes Funds’ advisory fees.

Based on these considerations, the Board concluded that the fees and total operating expenses of the Fund, in conjunction with other matters considered, are reasonable in light of the services provided.

### **Profitability**

The Board received and considered profitability information furnished by Federated Hermes, as requested by the CCO. Such profitability information included revenues reported on a fund-by-fund basis and estimates of the allocation of expenses made on a fund-by-fund basis, using allocation methodologies specified by the CCO and described to the Board. The Board considered the CCO’s view that, while these cost allocation reports apply consistent allocation processes, the inherent difficulties in allocating costs on a fund-by-fund basis continues to cause the CCO to question the precision of the process and to conclude that such reports may be unreliable because a single change in an allocation estimate may dramatically alter the resulting estimate of cost and/or profitability of a Federated Hermes Fund and may produce unintended consequences. In addition, the Board considered the CCO’s view that the allocation methodologies used by Federated Hermes in estimating profitability for purposes of reporting to the Board in connection with the continuation of the Contracts are consistent with the methodologies previously reviewed by an independent consultant. The Board noted that the independent consultant had previously conducted a review of the allocation methodologies and reported that, although there is no single best method to allocate expenses, the methodologies used by Federated Hermes are reasonable.

The Board also reviewed information compiled by Federated Hermes comparing its profitability information to other publicly held fund management companies, including information regarding profitability trends over time. The Board considered the CCO’s conclusion that, based on such profitability information, Federated Hermes’ profit margins did not appear to be excessive. The Board also considered the CCO’s view that Federated Hermes appeared financially sound, with the resources necessary to fulfill its obligations under its contracts with the Federated Hermes Funds.

### **Economies of Scale**

The Board received and considered information about the notion of possible realization of “economies of scale” as a fund grows larger, the difficulties of calculating economies of scale at an individual fund level, and the extent to which potential scale benefits are shared with shareholders. In this regard, the Board considered that Federated Hermes has made significant and long-term investments in areas that support all of the Federated Hermes Funds, such as: personnel, processes and tools for portfolio management, including the use of market data on which portfolio managers make investment decisions; trading operations; ESG integration and issuer engagement on ESG matters; shareholder services; compliance; business continuity; cybersecurity; internal audit and risk management functions; and technology that supports the provision of investment management services. The Board noted that Federated Hermes’ investments in these areas are extensive and are designed to provide enhanced services to the Federated Hermes Funds and their shareholders. The Board considered that the benefits of these investments are likely to be shared with the family of Federated Hermes Funds as a whole. In addition, the Board considered that fee waivers and expense reimbursements are another means for potential economies of scale to be shared with shareholders and can provide protection from an increase in expenses if a Federated Hermes Fund’s assets decline. The Board considered that, in order for the Federated Hermes Funds to remain competitive in the marketplace, Federated Hermes has frequently waived fees and/or reimbursed expenses for the Federated Hermes Funds and has disclosed to shareholders and/or reported to the Board its intention to do so (or continue to do so) in the future. The Board also considered Federated Hermes’ reductions in contractual management fees for certain Federated Hermes Funds during the prior year, including in response to the CCO’s recommendations in the prior year’s CCO Fee Evaluation Report, which have resulted in benefits being realized by shareholders.

The Board also considered reports on adviser-paid fees (commonly referred to as “revenue sharing”) that were provided to the Board throughout the year and in connection with the May Meetings. The Board considered that Federated Hermes and the CCO believe that this information should be viewed to determine if there was an incentive to either not apply breakpoints, or to apply breakpoints at higher levels, and should not be viewed to evaluate the reasonableness of advisory fees. The Board also noted the absence of any applicable regulatory or industry guidelines on this subject, which is compounded by the lack of any uniform methodology or pattern with respect to structuring fund advisory fees with breakpoints that serve to reduce the fees as a fund attains a certain size.

### **Other Benefits**

The Board considered information regarding the compensation and other ancillary (or “fall-out”) benefits that Federated Hermes derived from its relationships with the Federated Hermes Funds. The Board noted that, in addition to receiving advisory fees under the Federated Hermes Funds’ investment advisory contracts, Federated Hermes’ affiliates also receive fees for providing other services to the Federated Hermes Funds under separate contracts (e.g., for serving as the Federated Hermes Funds’ administrator and distributor). In this regard, the Board considered that certain of Federated Hermes’ affiliates provide distribution and shareholder services to the Federated Hermes Funds, for which they may be compensated through distribution and servicing fees paid pursuant to Rule 12b-1 plans or otherwise. The Board also received and considered information detailing any indirect benefit that Federated Hermes may derive from its receipt of research services from brokers who execute portfolio trades for the Federated Hermes Funds.

### **Conclusions**

The Board considered: (i) the CCO’s conclusion that his observations and the information accompanying the CCO Fee Evaluation Report show that the management fee for the Fund is reasonable; and (ii) the CCO’s recommendation that the Board approve the management fee. The Board noted that, under these circumstances, no changes were recommended to, and no objection was raised to the continuation of, the Contracts by the CCO. The CCO also recognized that the Board’s evaluation of the Federated Hermes Funds’ advisory and sub-advisory arrangements is a continuing and ongoing process that is informed by the information that the Board requests and receives from management throughout the course of the year and, in this regard, the CCO noted certain items for future reporting to the Board or further consideration by management as the Board continues its ongoing oversight of the Federated Hermes Funds.

On the basis of the information and factors summarized above, among other information and factors deemed relevant by the Board, and the evaluation thereof, the Board, including the Independent Trustees, unanimously voted to approve the continuation of the Contracts. The Board based its determination to approve the Contracts on the totality of the circumstances and relevant factors and with a view of past and future long-term considerations. Not all of the factors and considerations identified above were necessarily deemed to be relevant to the Fund, nor did the Board consider any one of them to be determinative. With respect to the factors that were deemed to be relevant, the Board’s determination to approve the continuation of the Contracts reflects its view that Federated Hermes’ performance and actions provided a satisfactory basis to support the determination to approve the continuation of the existing arrangements.

## Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness

In accordance with Rule 22e-4 under the Investment Company Act of 1940, as amended (the “Liquidity Rule”), Federated Hermes Insurance Series (the “Trust”) has adopted and implemented a liquidity risk management program (the “Program”) for Federated Hermes Kaufmann Fund II (the “Fund” and, collectively with the other non-money market open-end funds advised by Federated Hermes, the “Federated Hermes Funds”). The Program seeks to assess and manage the Fund’s liquidity risk. “Liquidity risk” is defined under the Liquidity Rule as the risk that the Fund is unable to meet redemption requests without significantly diluting remaining investors’ interests in the Fund. The Board of Trustees of the Trust (the “Board”) has approved the designation of each Federated Hermes Fund’s investment adviser as the administrator for the Program (the “Administrator”) with respect to that Fund. The Administrator, in turn, has delegated day-to-day responsibility for the administration of the Program to multiple Liquidity Risk Management Committees, which are comprised of representatives from certain divisions within Federated Hermes.

The Program is comprised of various components designed to support the assessment and/or management of liquidity risk, including: (1) the periodic assessment (no less frequently than annually) of certain factors that influence the Fund’s liquidity risk; (2) the periodic classification (no less frequently than monthly) of the Fund’s investments into one of four liquidity categories that reflect an estimate of their liquidity under current market conditions; (3) a 15% limit on the acquisition of “illiquid investments” (as defined under the Liquidity Rule); (4) to the extent a Fund does not invest primarily in “highly liquid investments” (as defined under the Liquidity Rule), the determination of a minimum percentage of the Fund’s assets that generally will be invested in highly liquid investments (an “HLIM”); (5) if a Fund has established an HLIM, the periodic review (no less frequently than annually) of the HLIM and the adoption of policies and procedures for responding to a shortfall of the Fund’s highly liquid investments below its HLIM; and (6) periodic reporting to the Board.

At its meetings in May 2022, the Board received and reviewed a written report (the “Report”) from the Federated Hermes Funds’ Chief Compliance Officer and Chief Risk Officer, on behalf of the Administrator, concerning the operation of the Program for the period from April 1, 2021 through March 31, 2022 (the “Period”). The Report addressed the operation of the Program and assessed its adequacy and effectiveness, including, where applicable, the operation of any HLIM established for a Federated Hermes Fund and each Federated Hermes Fund’s access to other available funding sources such as the Federated Hermes Funds’ interfund lending facility, redemptions in-kind, reverse repurchase agreement transactions, redemptions delayed beyond the normal T+1 settlement, but within seven days of the redemption request, and committed lines of credit. There were no material changes to the Program during the Period. The Report summarized the operation of the Program and the information and factors considered by the Administrator in assessing whether the Program has been adequately and effectively implemented with respect to the Federated Hermes Funds. Such information and factors included, among other things:

- confirmation that it was not necessary for the Fund to utilize, and the Fund did not utilize, alternative funding sources during the Period;
- the periodic classifications of the Fund’s investments into one of four liquidity categories and the methodologies and inputs used to classify the investments, including the Fund’s reasonably anticipated trade size;
- the analysis received from a third-party liquidity assessment vendor that is taken into account in the process of determining the liquidity classifications of the Fund’s investments and the results of an evaluation of the services performed by the vendor in support of this process;
- the fact that the Fund invested primarily in highly liquid investments during the Period and, therefore, was not required to establish, and has not established, an HLIM and the procedures for monitoring the status of the Fund as investing primarily in highly liquid investments;
- the fact that the Fund invested no more than 15% of its assets in illiquid investments during the Period and the procedures for monitoring this limit;
- the fact that there were no liquidity events during the Period, that materially affected the Fund’s liquidity risk;
- the impact on liquidity and management of liquidity risk caused by extended non-U.S. market closures and confirmation that there were no issues for any of the affected Federated Hermes Funds in meeting shareholder redemptions at any time during these temporary non-U.S. market closures;
- circumstances during the Period under which the Administrator convened meetings of the Liquidity Risk Management Committees more frequently than normal to conduct enhanced liquidity risk monitoring, including prior to the Russian invasion of Ukraine.

Based on this review, the Administrator concluded that the Program is operating effectively to assess and manage the Fund’s liquidity risk, and that the Program has been and continues to be adequately and effectively implemented to monitor and, as applicable, respond to the Fund’s liquidity developments.

## Voting Proxies on Fund Portfolio Securities

A description of the policies and procedures that the Fund uses to determine how to vote proxies, if any, relating to securities held in the Fund's portfolio is available, without charge and upon request, by calling 1-800-341-7400, Option #4. A report on "Form N-PX" of how the Fund voted any such proxies during the most recent 12-month period ended June 30 is available via the Proxy Voting Record (Form N-PX) link associated with the Fund and share class name at [FederatedInvestors.com/FundInformation](https://FederatedInvestors.com/FundInformation). Form N-PX filings are also available at the SEC's website at [sec.gov](https://sec.gov).

## Quarterly Portfolio Schedule

Each fiscal quarter, the Fund will file with the SEC a complete schedule of its monthly portfolio holdings on "Form N-PORT." The Fund's holdings as of the end of the third month of every fiscal quarter, as reported on Form N-PORT, will be publicly available on the SEC's website at [sec.gov](https://sec.gov) within 60 days of the end of the fiscal quarter upon filing. You may also access this information via the link to the Fund and share class name at [FederatedInvestors.com](https://FederatedInvestors.com).

Notes

*Variable investment options are not bank deposits or obligations, are not guaranteed by any bank and are not insured or guaranteed by the U.S. government, the Federal Deposit Insurance Corporation, the Federal Reserve Board or any other government agency. Investment in variable investment options involves investment risk, including the possible loss of principal.*

This Report is authorized for distribution to prospective investors only when preceded or accompanied by the Fund's Prospectus, which contains facts concerning its objective and policies, management fees, expenses and other information.



Federated Hermes Kaufmann Fund II  
Federated Hermes Funds  
4000 Ericsson Drive  
Warrendale, PA 15086-7561

Contact us at [FederatedInvestors.com](https://www.federatedinvestors.com)  
or call 1-800-341-7400.

Federated Securities Corp., Distributor

CUSIP 313916827  
CUSIP 313916777

28136 (2/23)

© 2023 Federated Hermes, Inc.